import streamlit as st
import google.generativeai as genai

# --- ğŸ¥ å©¦ç™Œè‡¨åºŠå°èˆªèˆ‡å¯¦è­‰åœ–æ›¸é¤¨ (2026 æ——è‰¦æœ€çµ‚æ¥µé‡æ•´åˆç‰ˆ) ---
st.set_page_config(page_title="å©¦ç™Œè‡¨åºŠè©¦é©—å°èˆªç³»çµ±", layout="wide")

# åˆå§‹åŒ– session_state ç”¨æ–¼è¯å‹•èˆ‡æŒä¹…åŒ–
if 'selected_trial' not in st.session_state:
    st.session_state.selected_trial = "ğŸ“š RUBY (ENGOT-EN6)"

st.markdown("""
    <style>
    @import url('https://fonts.googleapis.com/css2?family=Noto+Sans+TC:wght@400;700;900&family=Roboto:wght@400;700;900&display=swap');
    
    /* === UI é«˜å°æ¯”åº¦èˆ‡è¦–è¦ºæ•‘æ´ === */
    html, body, [class*="css"] {
        font-family: 'Noto Sans TC', 'Roboto', sans-serif;
        background-color: #F4F7F9; color: #1A1A1A;
        font-size: 19px !important; line-height: 1.1;
    }

    .main-title {
        font-size: 34px !important; font-weight: 900; color: #004D40;
        padding: 10px 0; border-bottom: 4px solid #4DB6AC; margin-bottom: 10px;
    }

    /* åœ–ä¸€ä¿®å¾©ï¼šå¤§éšæ®µ Header é£½å’Œæ¼¸å±¤èƒŒæ™¯ï¼Œç¢ºä¿ç™½è‰²æ–‡å­—æ¸…æ™° */
    .big-stage-card {
        border-radius: 12px; padding: 0px; box-shadow: 0 6px 25px rgba(0,0,0,0.15);
        border: 2.5px solid transparent; background: white; margin-bottom: 8px; overflow: hidden; height: auto !important;
    }
    .big-stage-header {
        font-size: 20px !important; font-weight: 900; color: white !important;
        padding: 14px; text-align: center; text-shadow: 1px 1px 3px rgba(0,0,0,0.5);
    }

    /* éšæ®µé…è‰²é£½å’ŒåŒ– */
    .card-p-tx { border-color: #1B5E20; }
    .header-p-tx { background: linear-gradient(135deg, #2E7D32, #1B5E20); } /* åˆæ²»: æ·±ç¶  */
    .card-p-mt { border-color: #0D47A1; }
    .header-p-mt { background: linear-gradient(135deg, #1565C0, #0D47A1); } /* ç¶­æŒ: æ·±è— */
    .card-r-tx { border-color: #BF360C; }
    .header-r-tx { background: linear-gradient(135deg, #E65100, #BF360C); } /* å¾©ç™¼: æ·±æ©˜ç´… */
    .card-r-mt { border-color: #4A148C; }
    .header-r-mt { background: linear-gradient(135deg, #6A1B9A, #4A148C); } /* å¾©å¾Œç¶­æŒ: æ·±ç´« */

    .sub-block {
        margin: 4px 8px; padding: 8px; border-radius: 10px; 
        background: #F8F9FA; border-left: 6px solid #455A64;
    }
    .sub-block-title {
        font-size: 16px; font-weight: 900; color: #263238;
        margin-bottom: 2px; border-bottom: 1.2px solid #CFD8DC; padding-bottom: 2px;
    }

    /* æŒ‰éˆ•æ¨£å¼ï¼šæ·±é»‘è‰²åŠ ç²— (#1A1A1A) */
    .stPopover button { 
        font-weight: 900 !important; font-size: 12px !important; 
        border-radius: 6px !important; margin-top: 3px !important;
        padding: 4px 10px !important; width: 100% !important; 
        text-align: left !important; color: #1A1A1A !important; 
        border: 1.5px solid rgba(0,0,0,0.2) !important;
        box-shadow: 0 2px 5px rgba(0,0,0,0.1) !important;
    }
    
    .stPopover button[aria-label*="ğŸ“š"] { background: #ECEFF1 !important; border-left: 6px solid #455A64 !important; }
    .stPopover button[aria-label*="ğŸ“"] { background: #E1F5FE !important; border-left: 6px solid #0288D1 !important; } 

    .detail-section { background: white; border-radius: 24px; padding: 35px; border: 1.5px solid #CFD8DC; box-shadow: 0 15px 50px rgba(0,0,0,0.1); }
    .hr-big-val { font-family: 'Roboto', sans-serif; font-size: 34px !important; font-weight: 900; color: #D84315; }
    .regimen-box { background: #F1F8E9; border-left: 6px solid #689F38; padding: 15px; border-radius: 8px; font-size: 15px; margin: 10px 0; line-height: 1.4; }
    .results-box { background: #FFF8E1; border: 1px solid #FFE082; padding: 10px; border-radius: 8px; margin-top: 5px; }
    </style>
    """, unsafe_allow_html=True)

# --- 1. æŒ‡å¼•æ•¸æ“šåº«ï¼šåˆ†å‹ã€éšæ®µèˆ‡è·¨çµ„å°èˆª ---
guidelines_nested = {
    "Endometrial": [
        {"id": "P-TX", "header": "åˆæ²» (Primary Tx)", "css": "p-tx", "subs": [
            {"title": "dMMR / MSI-H / MMRd", "content": "ä¸€ç·šé¦–é¸ï¼šå«é‰‘åŒ–ç™‚ + PD-1 (RUBY/GY018/AtTEnd)ã€‚"},
            {"title": "pMMR / NSMP / MSS", "content": "ä¸€ç·šç¶­æŒï¼šChemo + Durva/Ola (DUO-E)ã€‚äºŒç·šæ¨™é¶å…ç–« (KN775)ã€‚"},
            {"title": "POLE mutation (è¶…çªè®Šå‹)", "content": "é å¾Œæ¥µä½³ã€‚æ—©æœŸå¯è€ƒæ…®æ²»ç™‚é™éš (De-escalation)ã€‚"},
            {"title": "p53 mutation (é«˜æ‹·è²å‹)", "content": "ä¾µè¥²æ€§æœ€å¼·ã€‚å»ºè­°åŒ–æ”¾ç™‚ç©æ¥µä»‹å…¥ã€‚Serous å‹éœ€æª¢æ¸¬ HER2ã€‚"}]},
        {"id": "P-MT", "header": "ä¸€ç·šç¶­æŒ (1L Maint)", "css": "p-mt", "subs": [{"title": "Maintenance Therapy", "content": "ä¸€ç·š IO æ²»ç™‚å¾Œå»¶çºŒç¶­æŒè‡³ PD (MK2870-033/DUO-E)ã€‚"}]},
        {"id": "R-TX", "header": "å¾©ç™¼æ²»ç™‚ (Recurr Tx)", "css": "r-tx", "subs": [{"title": "Recurrent EC", "content": "æ¨™æº–äºŒç·šï¼šæ¨™é¶+å…ç–« (KN775) æˆ–å–®è—¥ IO (GARNET)ã€‚æ•‘æ´ ADC (SG)ã€‚"}]},
        {"id": "R-MT", "header": "å¾©å¾Œç¶­æŒ (PR-Maint)", "css": "r-mt", "subs": [{"title": "Continuous Therapy", "content": "æ•‘æ´æ²»ç™‚å¾Œç¶­æŒç•¶å‰æœ‰æ•ˆæ–¹æ¡ˆç›´åˆ°ç–¾ç—…é€²å±•ã€‚"}]}
    ],
    "Ovarian": [
        {"id": "P-TX", "header": "åˆæ²» (Primary Tx)", "css": "p-tx", "subs": [
            {"title": "HGSC / Endometrioid", "content": "æ‰‹è¡“ (PDS/IDS) + Carbo/Pacli Â± Bevã€‚IDS åŠ  HIPEC (van Driel)ã€‚"},
            {"title": "Low grade serous carcinoma", "content": "AI, MEK, CDK 4/6"},
            {"title": "Mucinous (MOC) é‘‘å®š", "content": "åˆ¤å®šï¼šCK7+/SATB2- (åŸç™¼)ã€‚IA æœŸå¯ä¿å®ˆã€‚ä¾µè¥²å‹å»ºè­°ç©æ¥µåŒ–ç™‚ã€‚"}]},
        {"id": "P-MT", "header": "ä¸€ç·šç¶­æŒ (1L Maint)", "css": "p-mt", "subs": [
            {"title": "BRCA mutation", "content": "Olaparib å–®è—¥ç¶­æŒ 2å¹´ (SOLO-1)ã€‚"}, 
            {"title": "HRD positive (wt)", "content": "PAOLA-1 (Ola+Bev) æˆ– PRIMA (Nira)ã€‚"},
            {"title": "HRD negative (pHRD)", "content": "Niraparib ç¶­æŒ (PRIMA ITT) æˆ– Bevacizumabã€‚"}]},
        {"id": "R-TX", "header": "å¾©ç™¼æ²»ç™‚ (Recurr Tx)", "css": "r-tx", "subs": [
            {"title": "PSOC (Sensitive Recur)", "content": "PFI > 6mã€‚è©•ä¼°äºŒæ¬¡æ‰‹è¡“ (DESKTOP III) æˆ–å«é‰‘è¤‡æ–¹ã€‚"},
            {"title": "PROC (Resistant Recur)", "content": "PFI < 6mã€‚å–®è—¥åŒ–ç™‚ Â± Bev æˆ–æ¨™é¶ ADC (MIRASOL)ã€‚"},
            {"title": "Low grade serous carcinoma", "content": "AI, MEK, CDK 4/6"}]},
        {"id": "R-MT", "header": "å¾©å¾Œç¶­æŒ (PR-Maint)", "css": "r-mt", "subs": [{"title": "PARPi Maint", "content": "æ•‘æ´ç·©è§£å¾ŒçºŒç”¨ PARPi (NOVA/ARIEL3/SOLO2)ã€‚"}]}
    ],
    "Cervical": [
        {"id": "P-TX", "header": "åˆæ²» (Primary Tx)", "css": "p-tx", "subs": [
            {"title": "Locally Advanced (CCRT)", "content": "åŒæ­¥åŒ–æ”¾ç™‚ Â± åŒæ­¥ IO (A18) æˆ– èª˜å°åŒ–ç™‚ (INTERLACE)ã€‚"},
            {"title": "Early Stage (Surgery)", "content": "æ ¹æ²»è¡“ (LACC) æˆ–å–®ç´”åˆ‡é™¤ (SHAPE)ã€‚"}]},
        {"id": "P-MT", "header": "ä¸€ç·šç¶­æŒ (1L Maint)", "css": "p-mt", "subs": [{"title": "Maintenance", "content": "1L æ–¹æ¡ˆå¾Œæ¥çºŒç¶­æŒ (KEYNOTE-826)ã€‚"}]},
        {"id": "R-TX", "header": "å¾©ç™¼æ²»ç™‚ (Recurr Tx)", "css": "r-tx", "subs": [
            {"title": "Recurr / Metastatic", "content": "ä¸€ç·š KN826/BEATccã€‚äºŒç·š ADC (innovaTV 301) æˆ– IO (EMPOWER)ã€‚"}]},
        {"id": "R-MT", "header": "å¾©å¾Œç¶­æŒ (PR-Maint)", "css": "r-mt", "subs": [{"title": "Continuous Therapy", "content": "ç¶­æŒç•¶å‰æœ‰æ•ˆæ•‘æ´æ–¹æ¡ˆç›´è‡³ PDã€‚"}]}
    ]
}

# --- 2. å¯¦è­‰è³‡æ–™åº« (33 é …è©¦é©—å…¨é‡æ•¸æ“šæ¥µé‡åŒ–è£œå®Œ) ---
all_trials_db = [
    # ==========================
    # === Endometrial Published ===
    # ==========================
    {"cancer": "Endometrial", "pos": "P-TX", "sub_pos": ["dMMR / MSI-H / MMRd"], "name": "ğŸ“š RUBY (ENGOT-EN6/GOG-3031)", "pharma": "GSK", "drug": "Dostarlimab + Carboplatin/Paclitaxel", 
     "pop_results": "dMMR/MSSï¼ˆpMMRï¼‰çš†é¡¯è‘—å»¶é•·PFSï¼ˆdMMRï¼šHR 0.28ï¼›å…¨é«”ï¼šHR 0.64ï¼‰ï¼Œä¸”æ›´æ–°åˆ†æé¡¯ç¤ºOSäº¦æ”¹å–„ï¼ˆdMMRï¼šHR 0.32ï¼›å…¨é«”ï¼šHR 0.69ï¼‰ï¼Œå¥ å®šä¸€ç·šã€Œå…ç–«ï¼‹åŒ–ç™‚ã€æ–°æ¨™æº–ã€‚",
     "rationale": "PD-1 é˜»æ–· (PD-1 blockade) èˆ‡å«é‰‘åŒ–ç™‚ (Carbo/Pacli) å…·å‚™å”åŒå…ç–«åŸæ€§ç´°èƒæ­»äº¡ (ICD) æ•ˆæ‡‰ã€‚è—‰ç”±åŒ–ç™‚èª˜å°è…«ç˜¤æŠ—åŸé‡‹æ”¾ï¼Œé‡‹æ”¾å…ç–«å¾®ç’°å¢ƒå£“åŠ›ä¸¦é‡å° MMRd æ—ç¾¤é”æˆæ¥µé«˜æŒä¹…æ‡‰ç­”ç‡ã€‚",
     "regimen": "Arm 1 (Dostarlimab çµ„): èª˜å°æœŸ: Dostarlimab 500mg Q3W + Carboplatin (AUC 5) + Paclitaxel (175 mg/m2) x6 é€±æœŸï¼›ç¶­æŒæœŸ: Dostarlimab 1000mg Q6W (æŒçºŒ 3å¹´)ã€‚ Arm 2 (Placebo çµ„): ç”Ÿç†é¹½æ°´å°ç…§ + åŒåŠ‘é‡ CP åŒ–ç™‚ x6 é€±æœŸã€‚",
     "inclusion": ["æ–°è¨ºæ–· FIGO Stage III-IV æˆ–é¦–æ¬¡å¾©ç™¼ä¹‹å­å®®å…§è†œç™Œ (EC)ã€‚", "ECOG 0-1ã€‚", "å« Carcinosarcoma / Clear cell / Serous ç­‰çµ„ç¹”å‹æ…‹ã€‚"],
     "exclusion": ["æ—¢å¾€æ¥å— PD-1/PD-L1 æ²»ç™‚ã€‚", "æ´»å‹•æ€§/éœ€ç³»çµ±æ€§æ²»ç™‚ä¹‹è‡ªé«”å…ç–«ç–¾ç—…ã€‚", "æœªæ§åˆ¶æ„ŸæŸ“ã€‚", "è‡¨åºŠä¸Šé¡¯è‘— CNS è½‰ç§»ç­‰ã€‚"],
     "outcomes": "dMMR æ—ç¾¤ 24å€‹æœˆ PFS ç‡: 61.4% vs 15.7% (HR 0.28, 95% CI 0.16-0.50); ITT å…¨äººç¾¤ mOS HR 0.64 (95% CI 0.46-0.87, P=0.0021)ã€‚"},

    {"cancer": "Endometrial", "pos": "P-TX", "sub_pos": ["dMMR / MSI-H / MMRd", "pMMR / NSMP / MSS"], "name": "ğŸ“š NRG-GY018 (KEYNOTE-868)", "pharma": "MSD", "drug": "Pembrolizumab + Carboplatin/Paclitaxel", 
     "pop_results": "Pembrolizumabï¼‹åŒ–ç™‚åœ¨ä¸€ç·šé¡¯è‘—å»¶é•·PFSï¼ˆdMMRï¼šHR 0.30ï¼›pMMRï¼šHR 0.54ï¼‰ï¼Œæ˜¯å¦ä¸€å€‹æ”¹è®Šè‡¨åºŠå¯¦å‹™çš„ä¸€ç·šå…ç–«ï¼‹åŒ–ç™‚é—œéµè©¦é©—ã€‚",
     "rationale": "åˆ©ç”¨å…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘ (ICI) é‡å¡‘è…«ç˜¤å¾®ç’°å¢ƒï¼ŒPembrolizumab å¼·åŒ–ä¸€ç·šå«é‰‘åŒ–ç™‚åæ‡‰å¾Œçš„æŒä¹…æ€§ã€‚",
     "regimen": "Arm A: Pembrolizumab 200mg Q3W + Carboplatin (AUC 5) + Paclitaxel (175 mg/m2) x6 é€±æœŸ -> ç¶­æŒæœŸ: Pembrolizumab 400mg Q6W (æŒçºŒ 2å¹´)ã€‚ Arm B: Placebo + CP x6 é€±æœŸã€‚",
     "inclusion": ["Stage III/IV æˆ–å¾©ç™¼ ECã€‚", "æä¾› MMR æª¢æ¸¬ (IHC) å ±å‘Šï¼Œåˆ†ç‚º dMMR vs pMMR å…©å€‹ä¸»è¦åˆ†æ cohortã€‚", "ECOG 0-1ã€‚"],
     "exclusion": ["æ—¢å¾€ antiâ€“PD-(L)1ã€‚", "æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚ã€‚", "ä¸å¯æ§åˆ¶å…±ç—…ï¼ˆæ„ŸæŸ“/å¿ƒè¡€ç®¡ç­‰ï¼‰ã€‚", "CNS æ´»å‹•æ€§ç—…ç¶ç­‰ã€‚"],
     "outcomes": "dMMR PFS HR 0.30 (95% CI 0.19-0.48); pMMR PFS HR 0.54 (95% CI 0.41-0.71, P<0.001)ã€‚"},

    {"cancer": "Endometrial", "pos": "P-TX", "sub_pos": ["pMMR / NSMP / MSS"], "name": "ğŸ“š DUO-E (ENGOT-EN9)", "pharma": "AZ", "drug": "Durvalumab + CP â†’ç¶­æŒ Â± Olaparib", 
     "pop_results": "ä¸€ç·šæ²»ç™‚ä¸­ï¼ŒDurvalumabï¼‹åŒ–ç™‚å¯æ”¹å–„PFSï¼ˆHR 0.71ï¼‰ï¼Œè€Œã€ŒDurvalumabï¼‹åŒ–ç™‚â†’ç¶­æŒåŠ ä¸ŠOlaparibã€æ•ˆç›Šæ›´å¤§ï¼ˆPFS HR 0.55ï¼‰ï¼›pMMRäº¦æœ‰PFSç²ç›Šï¼ˆDurva+Ola vs controlï¼šHR 0.57ï¼‰ï¼Œä¸”OSæœŸä¸­åˆ†ææ”¯æŒï¼ˆDurva+Ola vs controlï¼šHR 0.59ï¼‰ï¼Œä¸‰è—¥çµ„ pMMR PFS HR 0.57 (vs CP)",
     "rationale": "æ¢ç´¢ PARP æŠ‘åˆ¶åŠ‘ (PARPi) èˆ‡ PD-L1 æŠ‘åˆ¶åŠ‘åœ¨ç¶­æŒéšæ®µçš„å”åŒæ•ˆæœï¼ŒPARPi èª˜å°çš„ DNA æå‚·å¯å¢åŠ æ–°æŠ—åŸè² è·ï¼Œå¼·åŒ–å…ç–«æ‡‰ç­”ã€‚",
     "regimen": "Arm 1: carboplatin/paclitaxel + placebo â†’ placebo maintenance åƒ…åŒ–ç™‚ (å°ç…§çµ„); Arm 2: CP+Durvalumab -> Durva 1500mg Q4W ç¶­æŒ; Arm 3: CP+Durvalumab -> Durva 1500mg Q4W + Olaparib 300mg bid ç¶­æŒç›´åˆ°ç–¾ç—…é€²å±•ã€‚",
     "inclusion": ["newly diagnosed advanced æˆ– recurrent endometrial cancerã€‚", "é©åˆ CPã€‚", "ECOG 0-1ã€‚"],
     "exclusion": ["æ—¢å¾€å…ç–«æ²»ç™‚ / PARP inhibitorã€‚", "æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚ã€‚", "æœªæ§åˆ¶æ„ŸæŸ“ã€‚", "å…¶ä»–ç ”ç©¶è€…åˆ¤å®šä¸é©åˆç­‰ã€‚"],
     "outcomes": ["pMMR Arm 3 (Ola+Durva) vs Arm 1: PFS HR 0.57 (95% CI 0.42-0.79); dMMR Arm 2 vs Arm 1: HR 0.42 (95% CI 0.22-0.80)ã€‚", 
                  "PFSï¼šdurvalumab vs control HR 0.71ï¼›durvalumab+olaparib vs control HR 0.55ã€‚", 
                  "AEï¼ˆè‡¨åºŠé‡é»ï¼‰ï¼šåŠ ä¸Š olaparib å¾Œï¼Œéœ€ç‰¹åˆ¥æ³¨æ„ è²§è¡€/è¡€çƒä¸‹é™ã€ç–²å€¦ ç­‰ PARP å…¸å‹æ¯’æ€§ç–ŠåŠ ã€‚"]},

    {"cancer": "Endometrial", "pos": "P-TX", "sub_pos": ["dMMR / MSI-H / MMRd"], "name": "ğŸ“š AtTEnd (ENGOT-EN7)", "pharma": "Roche", "drug": "Atezolizumab + CP", 
     "pop_results": "Atezolizumabï¼‹åŒ–ç™‚åœ¨dMMRæ—ç¾¤PFSé¡¯è‘—æ”¹å–„ï¼ˆHR 0.36ï¼‰ï¼Œè¨Šæ¯é‡é»æ˜¯ã€Œæ•ˆç›Šä¸»è¦é›†ä¸­åœ¨dMMRã€ï¼ŒpMMRæ•´é«”æ•ˆç›Šç›¸å°ä¸æ˜é¡¯ï¼ŒdMMR PFS HR 0.36; ITT OS HR 0.82",
     "rationale": "é©—è­‰ä¸€ç·š PD-L1 æŠ‘åˆ¶åŠ‘ä½µç”¨åŒ–ç™‚å°æ™šæœŸæˆ–å¾©ç™¼æ‚£è€…ä¹‹ç”Ÿå­˜å„ªå‹¢ã€‚",
     "regimen": "Arm A: Atezolizumab 1200mg Q3W + CP x6-8 é€±æœŸ -> ç¶­æŒ Atezolizumab 1200mg Q3Wã€‚ Arm B: Placebo + CP x6-8 é€±æœŸã€‚",
     "inclusion": ["advanced æˆ– recurrent endometrial carcinomaã€‚", "ä¸€ç·šæ¥å— CPã€‚", "è©•ä¼° dMMR äºç¾¤ç²ç›Šã€‚"],
     "exclusion": ["æ—¢å¾€ PD-(L)1 æŠ‘åˆ¶åŠ‘ã€‚", "æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚ã€‚", "æœªæ§åˆ¶æ„ŸæŸ“ã€‚", "å…¶ä»–ç ”ç©¶è€…åˆ¤å®šä¸é©åˆç­‰ã€‚"],
     "outcomes": "dMMR PFS: æœªé”åˆ° vs 6.9m (HR 0.36, 95% CI 0.23-0.57); å…¨äººç¾¤ mOS HR 0.82 (P=0.048)ã€‚"},
    
    {"cancer": "Endometrial", 
    "pos": "P-MT", 
    "sub_pos": ["Maintenance Therapy"], 
    "name": "ğŸ“š DUO-E (Maint)", 
    "pharma": "AstraZeneca", 
    "drug": "Durvalumab Â± Olaparib",
    "pop_results": "ä¸€ç·šæ²»ç™‚ä¸­ï¼ŒDurvalumabï¼‹åŒ–ç™‚å¯æ”¹å–„PFSï¼ˆHR 0.71ï¼‰ï¼Œè€Œã€ŒDurvalumabï¼‹åŒ–ç™‚â†’ç¶­æŒåŠ ä¸ŠOlaparibã€æ•ˆç›Šæ›´å¤§ï¼ˆPFS HR 0.55ï¼‰ï¼›pMMRäº¦æœ‰PFSç²ç›Šï¼ˆDurva+Ola vs controlï¼šHR 0.57ï¼‰ï¼Œä¸”OSæœŸä¸­åˆ†ææ”¯æŒï¼ˆDurva+Ola vs controlï¼šHR 0.59ï¼‰",
    "rationale": "æ¢ç´¢ PARP æŠ‘åˆ¶åŠ‘èˆ‡ PD-L1 æŠ‘åˆ¶åŠ‘åœ¨ç¶­æŒéšæ®µå° pMMR æ‚£è€…çš„å”åŒå¢æ•æ•ˆæ‡‰ã€‚",
    "regimen": "Arm 2: Durvalumab 1500mg Q4W ç¶­æŒ; Arm 3: Durvalumab + Olaparib 300mg bid ç¶­æŒã€‚",
    "inclusion": ["ä¸€ç·šå«é‰‘åŒ–ç™‚å¾Œé” CR/PR ä¹‹æ™šæœŸ ECã€‚", "æä¾› MMR IHC ç‹€æ…‹ã€‚"],
    "exclusion": ["å…ˆå‰æ¥å—éç³»çµ±æ€§ IO æ²»ç™‚ã€‚"],
    "outcomes": "pMMR ä¸‰è—¥çµ„ (Ola+Durva) PFS HR 0.57 (95% CI 0.42-0.79)ã€‚"},
    
    {"cancer": "Endometrial", "pos": "R-TX", "sub_pos": ["Recurrent EC"], "name": "ğŸ“š KEYNOTE-775 (Study 309)", "pharma": "MSD/Eisai", "drug": "Lenvatinib + Pembrolizumab", 
     "pop_results": "Lenvatinibï¼‹Pembrolizumabåœ¨å¾©ç™¼/æ™šæœŸå­å®®å…§è†œç™Œç›¸è¼ƒåŒ–ç™‚åŒæ™‚æ”¹å–„PFSèˆ‡OSï¼ˆpMMRï¼šPFS HR 0.60ã€OS HR 0.68ï¼›å…¨é«”ï¼šPFS HR 0.56ã€OS HR 0.62ï¼‰ï¼Œç¢ºç«‹äºŒç·šä»¥å¾Œçš„é‡è¦çµ„åˆ",
     "rationale": "çµåˆ VEGF-TKI é‡å¡‘è¡€ç®¡ä¸¦æ¸›è¼•å…ç–«æŠ‘åˆ¶ï¼Œå…‹æœ MSS è…«ç˜¤ä¹‹å…ç–«å†·å¾®ç’°å¢ƒã€‚",
     "regimen": "Lenvatinib 20mg QD (æ¯æ—¥å£æœ) + Pembrolizumab 200mg Q3W (éœè„ˆæ»´æ³¨) ç›´è‡³ç–¾ç—…é€²å±•æˆ–ä¸å¯è€å—ã€‚",
     "inclusion": ["advanced/recurrent endometrial cancerã€‚", "å…ˆå‰æ¥å—éè‡³å°‘ä¸€æ¬¡å«é‰‘åŒ–ç™‚é€²å±•ä¹‹æ™šæœŸ EC (æœ€å¤šå‰ç·š 2 æ¬¡)ã€‚", "ECOG 0-1ã€‚", "ä¸é™ MMR ç‹€æ…‹ï¼Œä½†pMMR ç‚ºä¸»è¦æ—ç¾¤ä¹‹ä¸€ã€‚"],
     "exclusion": ["æ—¢å¾€ PD-1/PD-L1ã€‚", "æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚ã€‚", "æœªæ§åˆ¶é«˜è¡€å£“/é‡å¤§å¿ƒè¡€ç®¡é¢¨éšªï¼ˆlenvatinib ç›¸é—œï¼‰ã€‚", "å‡ºè¡€/å»”ç®¡é«˜é¢¨éšªç­‰ã€‚"],
     "outcomes": "pMMR OS: 17.4m vs 12.0m (HR 0.68, 95% CI 0.56-0.84, P<0.001); ITT OS: 18.3m vs 11.4m (HR 0.62)ï¼ŒPFS HR ~0.56; åæ‡‰ç‡äº¦å„ªæ–¼åŒ–ç™‚ï¼Œä½†æ¯’æ€§è¼ƒé«˜ï¼Œè‡¨åºŠå¸¸è¦‹ï¼šHTNã€è…¹ç€‰ã€ç–²å€¦ã€é«”é‡ä¸‹é™ã€ç”²ç‹€è…ºåŠŸèƒ½ç•°å¸¸ ç­‰ã€‚"},

    {"cancer": "Endometrial", "pos": "R-TX", "sub_pos": ["Recurrent EC"], "name": "ğŸ“š GARNET", "pharma": "GSK", "drug": "Dostarlimab å–®è—¥", 
     "pop_results": "å±¬å–®è‡‚Dostarlimabç ”ç©¶ï¼ˆä¸»è¦å ±ORR/æŒçºŒåæ‡‰ï¼‰ï¼Œç„¡éš¨æ©Ÿæ¯”è¼ƒHRå¯å¡«ï¼ˆHRï¼šN/Aï¼‰ï¼ŒdMMR ORR 45.5%; DOR æŒä¹…",
     "rationale": "é‡å° MSI-H/dMMR é«˜å…ç–«åŸæ€§æ‚£è€…ï¼Œå–®è—¥ PD-1 é˜»æ–·å³å¯é”æˆæŒä¹…æ‡‰ç­”ã€‚",
     "regimen": "Dostarlimab 500mg Q3W x4 åŠ‘ -> 1000mg Q6W ç¶­æŒç›´åˆ°é€²å±•ã€‚",
     "inclusion": ["recurrent/advanced endometrial cancerï¼Œå…ˆå‰æ²»ç™‚å¾Œã€‚", "åˆ† dMMR/MSI-H èˆ‡ pMMR cohortã€‚"],
     "exclusion": ["æ—¢å¾€ PD-1/PD-L1ã€‚", "æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚ã€‚", "CNS æ´»å‹•æ€§ç—…ç¶ç­‰"],
     "outcomes": "dMMR/MSI-H ORR 45.5%ã€ä¸” DoR é•·; DOR æœªé”åˆ°ã€‚pMMR ORR è¼ƒä½ï¼ˆç´„ 10â€“15% ç­‰ç´šï¼Œä¾åˆ†æé›†è€Œç•°ï¼‰"},

    # ==========================
    # === Cervical Published ===
    # ==========================
    {"cancer": "Cervical", "pos": "P-TX", "sub_pos": ["Locally Advanced (CCRT)"], "name": "ğŸ“š KEYNOTE-A18 (ENGOT-cx11)", "pharma": "MSD", "drug": "Pembrolizumab + CCRT", 
     "pop_results": "èˆ‡åŒæ­¥åŒ–æ”¾ç™‚ç›¸æ¯”ï¼ŒåŠ å…¥Pembrolizumabå¯å¸¶ä¾†æ•´é«”å­˜æ´»æ”¹å–„çš„è¶¨å‹¢/æ—©æœŸè¨Šè™Ÿï¼ˆæœŸä¸­OS HR 0.67ï¼‰ï¼Œæ ¸å¿ƒæ„ç¾©åœ¨æ–¼æŠŠå…ç–«æ²»ç™‚æ¨é€²åˆ°ã€Œæ ¹æ²»æ„åœ–ã€åŒæ­¥åŒ–æ”¾ç™‚å ´æ™¯ï¼ŒLACC æ¨™æº–ï¼š36m OS 82.6% (HR 0.67)",
     "rationale": "å°‡å…ç–«æ•´åˆå…¥é«˜é¢¨éšªå±€éƒ¨æ™šæœŸä¹‹æ ¹æ²»åŒæ­¥åŒ–æ”¾ç™‚ã€‚",
     "regimen": "Arm A: CCRT (Cisplatin 40mg/m2 é€±æœ + RT 45-50.4 Gy) åŒæ­¥ Pembro 200mg Q3W x5 é€±æœŸ -> ç¶­æŒ Pembro 400mg Q6W x15 é€±æœŸã€‚ Arm B: CCRT + Placeboã€‚",
     "inclusion": ["æ–°è¨ºæ–· Stage IB2-IIB LN(+) æˆ– Stage III-IVA å±€éƒ¨æ™šæœŸã€‚"],
     "exclusion": ["æ—¢å¾€ç³»çµ±æ€§æ²»ç™‚/å…ç–«æ²»ç™‚ã€‚", "æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚ã€‚", "ä¸å¯æ§æ„ŸæŸ“", "æ”¾ç™‚ç¦å¿Œç­‰"],
     "outcomes": "24m PFS: 68% vs 57% (HR 0.70); 36m OS: 82.6% vs 74.8% (HR 0.67)ã€‚"},

    {"cancer": "Cervical", "pos": "P-TX", "sub_pos": ["Locally Advanced (CCRT)"], "name": "ğŸ“š INTERLACE", "pharma": "UCL", "drug": "Induction Carbo/Pacli x6 -> CCRT", 
     "pop_results": "ä»¥ã€Œèª˜å°åŒ–ç™‚â†’å†åŒæ­¥åŒ–æ”¾ç™‚ã€ç­–ç•¥æ”¹å–„é å¾Œï¼Œå ±å‘Šé¡¯ç¤ºPFSèˆ‡OSçš†æå‡ï¼ˆPFS HR 0.65ï¼›OS HR 0.60ï¼‰ï¼Œä»£è¡¨ã€Œæ²»ç™‚åºåˆ—ã€æœ¬èº«ä¹Ÿèƒ½å¸¶ä¾†å­˜æ´»å¢ç›Šï¼Œ5å¹´ OS 80% (vs 72%, HR 0.60)",
     "rationale": "åˆ©ç”¨èª˜å°åŒ–ç™‚ (Induction Chemo) è§£æ±ºæ”¾ç™‚å‰çš„å¾®å°è½‰ç§»ã€‚",
     "regimen": "Arm Aï¼šèª˜å°æœŸ: induction chemotherapyï¼ˆçŸ­ç™‚ç¨‹ï¼‰Paclitaxel 80mg/m2 + Carboplatin AUC2 æ¯é€±ä¸€æ¬¡ x6 é€±æœŸ -> æ¥çºŒæ¨™æº– CCRT (Cisplatin + RT)ã€‚Arm Bï¼šæ¨™æº– CCRT alone",
     "inclusion": ["treatment-naÃ¯veã€locally advanced cervical cancerï¼Œé©åˆæ ¹æ²»æ€§ CCRTã€‚"],
     "exclusion": ["ç„¡æ³•æ¥å—åŒ–ç™‚æˆ–æ ¹æ²»æ€§æ”¾ç™‚ã€‚", "é‡å¤§å…±ç—…/æ„ŸæŸ“ã€‚", "æ‡·å­•ç­‰"],
     "outcomes": "5yr OS: 80% vs 72% (HR 0.60); 5yr PFS: 73% vs 64% (HR 0.65)ã€‚"},
    
    {"cancer": "Cervical", "pos": "P-MT", "sub_pos": ["Maintenance"], 
        "name": "ğŸ“š KEYNOTE-826", "pharma": "MSD", "drug": "Pembrolizumab + Chemo Â± Bev", 
        "pop_results": "ä¸€ç·š R/M å­å®®é ¸ç™Œé»ƒé‡‘æ¨™æº–ï¼šåœ¨åŒ–ç™‚åŸºç¤ä¸Šä½µç”¨å…ç–«æ²»ç™‚é¡¯è‘—æ”¹å–„ OS (HR 0.63)ã€‚å®Œæˆèª˜å°åŒ–ç™‚å¾Œï¼Œå…ç–«è—¥ç‰©æ¥çºŒç¶­æŒæ²»ç™‚ç›´è‡³ PD æˆ–æ»¿ 24 å€‹æœˆã€‚",
        "rationale": "åˆ©ç”¨å…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘èˆ‡åŒ–ç™‚ç”¢ç”Ÿå”åŒæ•ˆæ‡‰ï¼Œä¸¦é€éå¾ŒçºŒå–®è—¥å…ç–«ç¶­æŒæ²»ç™‚ï¼ŒæŒçºŒæ´»åŒ–å…ç–«ç³»çµ±ä»¥æ§åˆ¶è…«ç˜¤é€²å±•ã€‚",
        "regimen": "Arm 1: Pembrolizumab 200mg Q3W + Chemo (Pacli+Cis/Carbo) Â± Bevacizumab 15mg/kg Q3Wã€‚ Arm 2: Placebo + Chemo Â± Bevã€‚",
        "inclusion": ["persistent/recurrent/metastatic cervical cancer", "1L systemic therapy", "å¯æ¥å— Â± bev", "ä¸»è¦åˆ†æå¸¸ä»¥ PD-L1 CPS åˆ†å±¤"],
        "exclusion": ["æ—¢å¾€å…ç–«æ²»ç™‚ã€‚", "æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚ã€‚", "ä¸å¯æ§æ„ŸæŸ“ç­‰"],
        "outcomes": "CPSâ‰¥1 æ—ç¾¤ mOS: 28.6m vs 16.5m (HR 0.60); ITT å…¨äººç¾¤ OS HR 0.63; Grade â‰¥3 AE æ¯”ä¾‹é«˜ï¼ˆåŒ–ç™‚èƒŒæ™¯ç‚ºä¸»ï¼›åŠ  pembro å¾Œå…ç–«ç›¸é—œ AE å¢åŠ ï¼‰"},

    {"cancer": "Cervical", "pos": "R-TX", "sub_pos": ["Recurr / Metastatic"], "name": "ğŸ“š innovaTV 301 (ENGOT-cx12)", "pharma": "Genmab", "drug": "Tisotumab Vedotin (ADC)", 
     "pop_results": "Tisotumab vedotinç›¸è¼ƒé†«å¸«é¸æ“‡åŒ–ç™‚æ”¹å–„OSï¼ˆOS HR 0.70ï¼‰ï¼Œä»£è¡¨ADCåœ¨å¾©ç™¼/è½‰ç§»é ¸ç™Œçš„é‡Œç¨‹ç¢‘ï¼Œå¾Œç·š ADC çªç ´ï¼šOS HR 0.70; ORR 17.8%",
     "rationale": "æ¨™é¶çµ„ç¹”å› å­ (Tissue Factor) ADCï¼Œè§£æ±ºå¾Œç·šåŒ–ç™‚è€è—¥ã€‚",
     "regimen": "Arm A: Tisotumab Vedotin 2.0 mg/kg IV Q3Wã€‚ Arm B: é†«å¸«é¸æ“‡åŒ–ç™‚ (Chemo SoC)ã€‚",
     "inclusion": ["recurrent/metastatic cervical cancerã€‚", "2L/3L æ²»ç™‚æƒ…å¢ƒï¼ˆä¾è©¦é©—ï¼‰"],
     "exclusion": ["ä¸é©åˆ ADC/æ—¢å¾€ç›¸é—œè—¥ç‰©é™åˆ¶ã€‚", "åš´é‡è§’è†œ/çœ¼éƒ¨é¢¨éšªéœ€è©•ä¼°ï¼ˆTV å¸¸è¦‹çœ¼æ¯’æ€§ç®¡ç†ï¼‰ã€‚", "å…¶ä»–å…±ç—…ç­‰"],
     "outcomes": "mOS: 11.5m vs 9.5m (HR 0.70); ORR 17.8% vs 5.2%ã€‚AEåŒ…æ‹¬å‡ºè¡€ã€å‘¨é‚Šç¥ç¶“ç—…è®Šã€çœ¼éƒ¨ AEï¼ˆéœ€é é˜²æ€§çœ¼è—¥æ°´/çœ¼ç§‘ç›£æ¸¬ï¼‰"},

    {"cancer": "Cervical", "pos": "P-TX", "sub_pos": ["Locally Advanced (CCRT)"], 
        "name": "ğŸ“š CALLA", "pharma": "AZ", "drug": "Durvalumab + CCRT", 
        "pop_results": "æ•´é«”è©¦é©—çµæœç‚ºé™°æ€§ã€‚åœ¨å±€éƒ¨æ™šæœŸå­å®®é ¸ç™Œä¸­ï¼ŒåŒæ­¥åŒ–æ”¾ç™‚åŠ å…¥ Durvalumab ä¸¦æœªé¡¯è‘—æ”¹å–„ PFS (HR 0.84; P=0.174)ã€‚",
        "rationale": "æ¢ç´¢ PD-L1 æŠ‘åˆ¶åŠ‘èˆ‡åŒæ­¥åŒ–æ”¾ç™‚ (CCRT) è¯ç”¨æ˜¯å¦èƒ½ç”¢ç”Ÿå”åŒå…ç–«æ•ˆæ‡‰ã€‚",
        "regimen": "Arm Aï¼šdurvalumab + CCRTï¼ˆä¸¦æ–¼ CCRT å¾ŒæŒçºŒ durvalumabï¼‰ã€‚ Arm Bï¼šplacebo + CCRTï¼ˆä¸¦æ–¼å¾ŒçºŒæŒçºŒ placeboï¼‰ã€‚",
        "inclusion": ["untreated locally advanced cervical cancerï¼Œæ¥å—æ ¹æ²»æ€§ CCRTã€‚"],
        "exclusion": ["æ—¢å¾€å…ç–«æ²»ç™‚ã€‚", "æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚ã€‚", "æ”¾ç™‚/åŒ–ç™‚ç¦å¿Œç­‰"],
        "outcomes": "PFSæœªé”é¡¯è‘—ï¼ŒHR 0.84 (95% CI 0.65-1.08)ï¼Œé¡¯ç¤ºã€Œall-comersã€ä¸‹åŠ  durvalumab æœªèƒ½æˆç‚ºæ–°æ¨™æº–ï¼ˆå¯èƒ½éœ€ biomarker ç²¾é¸ï¼‰ã€‚"},
    
    {"cancer": "Cervical", "pos": "R-TX", "sub_pos": ["Recurr / Metastatic"], 
        "name": "ğŸ“š EMPOWER-Cervical 1", "pharma": "Regeneron", "drug": "Cemiplimab å–®è—¥", 
        "pop_results": "äºŒç·šå¾Œå–®è—¥å…ç–«æ²»ç™‚é‡è¦æŒ‡æ¨™ï¼šç›¸è¼ƒåŒ–ç™‚é¡¯è‘—å»¶é•· OS (mOS 12.0m vs 8.5m; HR 0.69)ï¼Œä¸è«–çµ„ç¹”å‹æ…‹å‡æœ‰ç²ç›Šã€‚",
        "rationale": "é‡å°ä¸€ç·šé‰‘é¡åŒ–ç™‚å¤±æ•—å¾Œä¹‹æ‚£è€…ï¼Œåˆ©ç”¨ PD-1 é˜»æ–·æä¾›æŒä¹…ç·©è§£èˆ‡ç”Ÿå­˜å„ªå‹¢ã€‚",
        "regimen": "Arm Aï¼šcemiplimabã€‚ Arm Bï¼šphysicianâ€™s choice single-agent chemoã€‚",
        "inclusion": ["recurrent/metastatic cervical cancerã€‚", "progressed after 1L platinum"],
        "exclusion": ["æ—¢å¾€å…ç–«æ²»ç™‚ã€‚", "æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚ã€‚", "ä¸å¯æ§æ„ŸæŸ“ç­‰"],
        "outcomes": "OS é¡¯è‘—æ”¹å–„ï¼ŒITT å…¨äººç¾¤ OS HR 0.69 (95% CI 0.56-0.84)ã€‚"},
    
    { "cancer": "Cervical", "pos": "R-TX", "sub_pos": ["Recurr / Metastatic"], 
        "name": "ğŸ“š BEATcc", "pharma": "Roche", "drug": "Atezolizumab + Chemo + Bev", 
        "pop_results": "ä¸€ç·š R/M å­å®®é ¸ç™Œï¼šåœ¨åŒ–ç™‚+æ¨™é¶åŸºç¤ä¸ŠåŠ å…¥ Atezolizumabï¼Œé¡¯è‘—å»¶é•· PFS (13.7m vs 10.4m) èˆ‡ OS (32.1m vs 22.8m)ï¼ŒPFS HR 0.62ï¼›OS HR 0.68ï¼‰ã€‚",
        "rationale": "PD-L1 é˜»æ–·ä½µç”¨ VEGF æŠ‘åˆ¶åŠ‘èˆ‡åŒ–ç™‚ï¼Œä¸‰è»Œè¯ç”¨å¼·åŒ–è…«ç˜¤å¾®ç’°å¢ƒä¹‹æ®ºå‚·åŠ›ã€‚",
        "regimen": "Arm Aï¼šatezolizumab + bevacizumab + platinum chemoï¼ˆå« paclitaxelï¼‰ â†’ atezolizumab + bev maintenanceã€‚ Arm Bï¼šbevacizumab + platinum chemo â†’ bev maintenanceã€‚",
        "inclusion": ["untreated metastatic/persistent/recurrent cervical cancerã€‚", "å¯æ¥å—å« bev çš„æ¨™æº–ä¸€ç·š"],
        "exclusion": ["æ—¢å¾€å…ç–«æ²»ç™‚ã€‚", "æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚ã€‚", "ä¸é©åˆ bevï¼ˆå‡ºè¡€/å»”ç®¡/è¡€æ “é«˜é¢¨éšªç­‰ï¼‰"],
        "outcomes": "mPFS HR 0.62; mOS HR 0.68 (95% CI 0.52-0.88)ã€‚PFS èˆ‡ OS çš†é¡¯è‘—æ”¹å–„ï¼Œå»ºç«‹ã€ŒPD-L1 inhibitor + GOG240 backboneã€çš„æ–°ä¸€ç·šé¸é …"},
    
    {"cancer": "Cervical", "pos": "P-TX", "sub_pos": ["Early Stage (Surgery)"], 
        "name": "ğŸ“š LACC", "pharma": "NEJM", "drug": "Open vs MIS Radical Hysterectomy", 
        "pop_results": "æ”¹è®Šæ‰‹è¡“æ¨™æº–ä¹‹ç ”ç©¶ï¼šå¾®å‰µæ‰‹è¡“ (MIS) ç›¸è¼ƒæ–¼å‚³çµ±é–‹è…¹æ‰‹è¡“ï¼Œå…¶å¾©ç™¼é¢¨éšªè¼ƒé«˜ä¸”ä¸‰å¹´å­˜æ´»ç‡è¼ƒä½ã€‚",
        "rationale": "è©•ä¼°é”æ–‡è¥¿/è…¹è…”é¡å¾®å‰µæ‰‹è¡“åœ¨å­å®®é ¸ç™Œæ ¹æ²»è¡“ä¸­ï¼Œæ˜¯å¦èƒ½é”æˆèˆ‡é–‹è…¹æ‰‹è¡“åŒç­‰çš„é å¾Œã€‚",
        "outcomes": "DFS Rate: 91.2% (MIS) vs 97.1% (Open); HR for recurrence 3.74ã€‚"},
    
    {"cancer": "Cervical", "pos": "P-TX", "sub_pos": ["Early Stage (Surgery)"], 
        "name": "ğŸ“š SHAPE", "pharma": "CCTG", "drug": "Simple vs Radical Hysterectomy", 
        "pop_results": "ä½é¢¨éšªé™éšé¸æ“‡ï¼šå°æ–¼è…«ç˜¤ <2cm ä¹‹ä½é¢¨éšªæ‚£è€…ï¼Œå–®ç´”å­å®®åˆ‡é™¤åœ¨ä¸‰å¹´ç›†è…”å¾©ç™¼ç‡ä¸Šä¸åŠ£æ–¼å»£æ³›æ€§å­å®®åˆ‡é™¤ã€‚",
        "rationale": "æ—¨åœ¨æ¸›å°‘æ—©æœŸæ‚£è€…æ¥å—éåº¦æ‰‹è¡“æ²»ç™‚æ‰€å°è‡´çš„ä½µç™¼ç—‡èˆ‡ç”Ÿæ´»å“è³ªå—æã€‚",
        "outcomes": "3yr Pelvic Recurrence: 2.52% (Simple) vs 2.17% (Radical); P<0.05 (éåŠ£æ€§)ã€‚"},
    
    # ==========================
    # === Ovarian Published ===
    # ==========================
    {"cancer": "Ovarian", "pos": "R-TX", "sub_pos": ["PROC (Resistant Recur)"], "name": "ğŸ“š MIRASOL (GOG-3045)", "pharma": "ImmunoGen", "drug": "Mirvetuximab Soravtansine", 
     "pop_results": "åœ¨FRÎ±é«˜è¡¨ç¾ã€é‰‘æŠ—è—¥åµå·¢ç™Œä¸­ï¼ŒMirvetuximabè¼ƒåŒ–ç™‚æ”¹å–„PFSèˆ‡OSï¼ˆPFS HR 0.65ï¼›OS HR 0.67ï¼‰ï¼Œç¢ºç«‹FRÎ± ADCçš„é—œéµåœ°ä½ï¼ŒPROC OS çªç ´ï¼šOS HR 0.67; ORR 42.3%",
     "rationale": "é‡å° FRÎ± é«˜è¡¨ç¾ PROC æ‚£è€…ï¼Œé¦–å€‹ ADC ç”Ÿå­˜ç²ç›Šç ”ç©¶ã€‚",
     "regimen": "æ—ç¾¤ï¼šFRÎ±-highã€platinum-resistantï¼ˆä¾ IHC é–€æª»ï¼‰ã€‚Arm A: Mirvetuximab 6.0 mg/kg (AIBW) IV Q3W ç›´è‡³é€²å±•ã€‚ Arm B: é†«å¸«é¸æ“‡åŒ–ç™‚ å¦‚ weekly paclitaxel / PLD / topotecanï¼‰ã€‚",
     "inclusion": ["platinum-resistant é«˜ç´šåˆ¥æ¼¿æ¶²æ€§ç‚ºä¸»ã€‚", "FRÎ± é«˜è¡¨ç¾ã€‚", "æ—¢å¾€æ²»ç™‚ç·šæ•¸ä¾è©¦é©—ã€‚"],
     "exclusion": ["ä¸ç¬¦åˆ FRÎ± é–€æª»ã€‚", "ä¸å¯æ§çœ¼éƒ¨/ç¥ç¶“æ¯’æ€§é¢¨éšªã€‚"],
     "outcomes": "mOS: 16.4m vs 12.7m (HR 0.67); mPFS 5.6m vs 4.0m (HR 0.65)ã€‚ORR äº¦é¡¯è‘—è¼ƒä½³ï¼›Grade â‰¥3 AE è¼ƒå°‘"},
    
    {"cancer": "Ovarian", "pos": "P-TX", "sub_pos": ["Low grade serous carcinoma"], 
        "name": "ğŸ“ NRG-GY019", "pharma": "NRG Oncology", "drug": "Letrozole vs Chemoâ†’Letrozole", 
        "pop_results": "ä¸€ç·šå»åŒ–ç™‚æŒ‘æˆ°ï¼šè©•ä¼°å°æ–¼æ–°è¨ºæ–· LGSOC æ‚£è€…ï¼Œå–®ç”¨ Letrozole æ˜¯å¦ä¸åŠ£æ–¼å‚³çµ±åŒ–ç™‚å¾Œæ¥çºŒç¶­æŒæ²»ç™‚ã€‚",
        "rationale": "ä½æƒ¡æ€§åº¦æ¼¿æ¶²æ€§ç™Œ (LGSOC) å°å‚³çµ±åŒ–ç™‚åæ‡‰ç‡è¼ƒä½ï¼Œæ­¤ç ”ç©¶æ—¨åœ¨é©—è­‰åˆæœŸå³ä½¿ç”¨å…§åˆ†æ³Œæ²»ç™‚çš„è‡¨åºŠæ•ˆç›Šã€‚",
        "regimen": "Arm 1: Letrozole (2.5mg QD) å–®è—¥æ²»ç™‚ç›´åˆ°é€²å±•ï¼›Arm 2: å‚³çµ± 6 é€±æœŸåŒ–ç™‚ (CP) å¾Œæ¥çºŒ Letrozole ç¶­æŒæ²»ç™‚ã€‚",
        "inclusion": ["æ–°è¨ºæ–· Stage II-IV ä½æƒ¡æ€§åº¦æ¼¿æ¶²æ€§åµå·¢ç™Œ/è…¹è†œç™Œ", "ECOG 0-2", "éœ€æä¾›çµ„ç¹”å­¸åˆ¤å®šå ±å‘Š"],
        "exclusion": ["æ›¾å—éé‡å°æ­¤ç–¾ç—…ä¹‹å…¨èº«æ€§åŒ–ç™‚æˆ–æ¨™é¶æ²»ç™‚", "è¨ˆç•«æ¥å—ç¶­æŒæ€§ PARPi æ²»ç™‚è€…"],
        "outcomes": "æ‹›å‹Ÿä¸­ (Ongoing Recruitment)ã€‚"},
    
    {"cancer": "Ovarian", "pos": "R-TX", "sub_pos": ["PSOC (Sensitive Recur)"], "name": "ğŸ“š DESKTOP III", "pharma": "AGO", "drug": "Secondary Cytoreduction Surgery", 
     "pop_results": "å¾©ç™¼åµå·¢ç™Œåœ¨åš´æ ¼é¸äººï¼ˆå¦‚AGO scoreï¼‰ä¸‹ï¼Œæ¬¡æ¸›ç©æ‰‹è¡“å¸¶ä¾†OSæ”¹å–„ï¼ˆæ­»äº¡HR 0.75ï¼‰ï¼Œå¥ å®šã€Œé¸å°äººåšæ‰‹è¡“ã€çš„åƒ¹å€¼ï¼ŒäºŒæ¬¡æ‰‹è¡“åƒ¹å€¼ï¼šR0 åˆ‡é™¤ mOS 53.7m",
     "rationale": "è­‰æ˜åš´é¸æ‚£è€… (AGO Score+) äºŒæ¬¡æ‰‹è¡“å…·ç”Ÿå­˜ç²ç›Šã€‚",
     "regimen": "platinum-sensitive recurrent ovarian cancerï¼ˆä»¥ AGO score ç­‰æ¢ä»¶ç¯©é¸å¯å®Œå…¨åˆ‡é™¤è€…ï¼‰ã€‚æ‰‹è¡“çµ„: è…«ç˜¤å®Œå…¨åˆ‡é™¤æ‰‹è¡“å¾Œæ¥çºŒå«é‰‘åŒ–ç™‚ã€‚ åŒ–ç™‚çµ„: å–®ç´”å«é‰‘è¤‡æ–¹åŒ–ç™‚ã€‚",
     "inclusion": ["é¦–æ¬¡é‰‘é¡æ•æ„Ÿå¾©ç™¼ (PFI > 6m)ã€‚", "å¯æœ›é”åˆ° complete resectionï¼ŒAGO Score é™½æ€§ (ECOG 0/å¤§é‡è…¹æ°´é™¤å¤–/R0 å®Œå…¨åˆ‡é™¤æ½›åŠ›)ã€‚"],
     "exclusion": ["ç„¡æ³•é”åˆ° R0 æˆ–æ‰‹è¡“é¢¨éšªéé«˜ã€‚", "å…¶ä»–é‡å¤§å…±ç—…ã€‚"],
     "outcomes": "ITT mOS: 53.7m vs 46.0m (HR 0.75, 95% CI 0.59-0.96); R0 åˆ‡é™¤è€… mOS é” 61.9mï¼ˆæ‰‹è¡“çµ„è¼ƒä½³ï¼Œå‰ææ˜¯é«˜æ¯”ä¾‹ R0ï¼‰ã€‚"},

    {"cancer": "Ovarian", "pos": "P-TX", "sub_pos": ["HGSC / Endometrioid"], "name": "ğŸ“š van Driel HIPEC", "pharma": "NEJM", "drug": "Surgery + HIPEC (Cisplatin)", 
     "pop_results": "é–“éš”æ¸›ç©æ‰‹è¡“åŠ å…¥HIPECå¯æ”¹å–„OSï¼ˆæ­»äº¡é¢¨éšªä¸‹é™ï¼šOS HR 0.67ï¼‰ï¼Œç‚ºã€Œç‰¹å®šä¸€ç·šæ‰‹è¡“æƒ…å¢ƒã€å¼•å…¥HIPECçš„é‡è¦è­‰æ“šï¼ŒIDS åŠ æº«ï¼šmOS å»¶é•· 12 å€‹æœˆ (HR 0.67)",
     "rationale": "è¡“ä¸­åŠ æº«è…¹è…”åŒ–ç™‚å¼·åŒ–ç‰©ç†æ®ºå‚·èˆ‡æ»²é€åŠ›ã€‚",
     "regimen": "stage IIIã€NACT å¾Œ é–“æ­‡æ¸›ç©æ‰‹è¡“ (IDS) æ™‚åŒæ­¥é€²è¡ŒåŠ æº« (42Â°C) è…¹è…”çŒæ³¨ Cisplatin (100 mg/m2) 90 åˆ†é˜ã€‚Arm Aï¼šsurgery + HIPEC cisplatinï¼ˆå¸¸è¦‹ 100 mg/mÂ²ã€90 åˆ†é˜ï¼‰+ å¾ŒçºŒåŒ–ç™‚ã€‚Arm Bï¼šsurgeryï¼ˆno HIPECï¼‰+ å¾ŒçºŒåŒ–ç™‚ã€‚",
     "inclusion": ["stage III epithelial ovarian cancerã€‚", "NACT å¾Œé©åˆ interval debulkingã€‚"],
     "exclusion": ["ä¸é©åˆå¤§æ‰‹è¡“æˆ– HIPECï¼ˆè…åŠŸèƒ½ã€å…¨èº«ç‹€æ³ç­‰ï¼‰ã€‚", "å…¶ä»–é‡å¤§å…±ç—…ã€‚"],
     "outcomes": "mOS: 45.7m vs 33.9m (HR 0.67, 95% CI 0.48-0.94)ã€‚recurrence-free survival äº¦æ”¹å–„ï¼›Grade 3â€“4 AE ç‡ç›¸è¿‘ã€‚"},

    {"cancer": "Ovarian", "pos": "P-TX", "sub_pos": ["HGSC / Endometrioid"], "name": "ğŸ“š LION", "pharma": "NEJM", "drug": "No Lymphadenectomy", 
     "pop_results": "ç³»çµ±æ€§æ·‹å·´æ¸…æƒä¸æ”¹å–„å­˜æ´»ï¼ˆOS HR 1.06ï¼›PFS HR 1.11ï¼‰ä¸”ä½µç™¼ç—‡å¢åŠ ï¼Œæ”¹è®Šäº†ã€Œå¤–è§€æ­£å¸¸æ·‹å·´çµã€æ‚£è€…çš„æ‰‹è¡“ç¯„å¼ï¼Œè‡¨åºŠ LN é™°æ€§å…æ¸…æƒï¼šOS ç„¡å·®ç•° (HR 1.06)",
     "regimen": "åœ¨ã€Œè‡¨åºŠ/å½±åƒé™°æ€§æ·‹å·´çµã€ä¸”å®Œæˆè…«ç˜¤åˆ‡é™¤çš„ advanced ovarian cancerã€‚Arm Aï¼šsystematic pelvic + para-aortic lymphadenectomyã€‚Arm Bï¼šno lymphadenectomyã€‚",
     "inclusion": ["advanced ovarian cancerã€‚", "complete resectionã€‚", "æ·‹å·´çµè‡¨åºŠé™°æ€§ã€‚"],
     "exclusion": ["æ˜é¡¯æ·‹å·´çµç—…ç¶ã€‚", "ç„¡æ³•è€å—æ‰‹è¡“å»¶é•·ã€‚"],
     "outcomes": "OS HR 1.06ï¼ˆç„¡ç²ç›Šï¼‰ï¼›PFS äº¦ç„¡å·®ï¼›ä½†æ‰‹è¡“ä½µç™¼ç—‡å¢åŠ ã€‚mOS: 65.5m vs 69.2m (HR 1.06)ã€‚è‡¨åºŠ LN(-) è€…å…æ¸…æƒã€‚"},

    {"cancer": "Ovarian", "pos": "R-TX", "sub_pos": ["Low grade serous carcinoma"], 
        "name": "ğŸ“š GOG-281 / LOGS", "pharma": "Targeted", "drug": "Trametinib", 
        "pop_results": "LGSOC æ¨™é¶é‡å¤§çªç ´ï¼šèˆ‡é†«å¸«é¸æ“‡åŒ–ç™‚ç›¸æ¯”ï¼ŒTrametinib é¡¯è‘—é™ä½ 52% ç–¾ç—…é€²å±•é¢¨éšª (HR 0.48)ï¼ŒORR é” 26%ã€‚",
        "rationale": "é‡å°ä½æƒ¡æ€§åº¦æ¼¿æ¶²æ€§åµå·¢ç™Œ (LGSOC) ä¸­å¸¸è¦‹çš„ MAPK è·¯å¾‘ç•°å¸¸æ´»åŒ–ï¼Œåˆ©ç”¨ MEK æŠ‘åˆ¶åŠ‘é€²è¡Œç²¾æº–æ¨™é¶é˜»æ–·ã€‚",
        "regimen": "Trametinib 2.0 mg æ¯æ—¥å£æœä¸€æ¬¡ï¼ŒæŒçºŒæ²»ç™‚ç›´åˆ°ç–¾ç—…é€²å±•æˆ–ä¸å¯è€å—ä¹‹æ¯’æ€§ã€‚",
        "inclusion": ["å¾©ç™¼æ€§ä½æƒ¡æ€§åº¦æ¼¿æ¶²æ€§åµå·¢ç™Œ/è…¹è†œç™Œ", "å…ˆå‰æ¥å—éè‡³å°‘ä¸€æ¬¡å«é‰‘åŒ–ç™‚", "ECOG 0-1"],
        "exclusion": ["æ›¾å—éå…¶ä»– MEK æŠ‘åˆ¶åŠ‘æ²»ç™‚", "è‡¨åºŠé¡¯è‘—çš„å¿ƒè‡ŸåŠŸèƒ½ç•°å¸¸"],
        "outcomes": "mPFS: 13.0m (vs 7.2m, HR 0.48, 95% CI 0.36-0.64)ã€‚"},
    
    {"cancer": "Ovarian", "pos": "R-TX", "sub_pos": ["Low grade serous carcinoma"], 
        "name": "ğŸ“ RAMP-201", "pharma": "Verastem Oncology", "drug": "Avutometinib + Defactinib", 
        "pop_results": "LGSOC é›™é‡é˜»æ–·æ–°é«˜åº¦ï¼šKRAS çªè®Šæ—ç¾¤ ORR é«˜é” 55%ï¼›å…¨é«”æ—ç¾¤ ORR é” 45%ã€‚",
        "rationale": "çµåˆ RAF/MEK é›™é‡æŠ‘åˆ¶åŠ‘ (Avutometinib) èˆ‡ FAK æŠ‘åˆ¶åŠ‘ (Defactinib)ï¼Œæ—¨åœ¨å…‹æœå–®ä¸€é€šè·¯é˜»æ–·å¾Œç”¢ç”Ÿçš„è£œå„Ÿæ€§è€è—¥æ©Ÿåˆ¶ã€‚",
        "regimen": "Avutometinib 3.2 mg (å…©æ¬¡/é€±) + Defactinib 200 mg (å…©æ¬¡/æ—¥)ï¼Œæ¡ 3 é€±çµ¦è—¥ 1 é€±ä¼‘æ¯ä¹‹é€±æœŸè¨­è¨ˆã€‚",
        "inclusion": ["å¾©ç™¼æ€§ LGSOC (ä¸é™ KRAS ç‹€æ…‹)", "å…ˆå‰æ¥å—éå«é‰‘åŒ–ç™‚åŠæ¨™é¶æ²»ç™‚", "æä¾›è…«ç˜¤çµ„ç¹”æ¨£å“"],
        "exclusion": ["æ´»å‹•æ€§è…¦è½‰ç§»", "æ›¾å—éåŒé¡ FAK æŠ‘åˆ¶åŠ‘æ²»ç™‚"],
        "outcomes": "KRAS mut ORR: 55%; å…¨é«” ORR: 45% (åˆæ­¥æ•¸æ“šäº®çœ¼)ã€‚"},
    
    {"cancer": "Ovarian", "pos": "R-TX", "sub_pos": ["Low grade serous carcinoma"], 
        "name": "ğŸ“š GOG-3026", "pharma": "Novartis", "drug": "Ribociclib + Letrozole", 
        "pop_results": "LGSOC å»åŒ–ç™‚çµ„åˆï¼šCDK4/6 æŠ‘åˆ¶åŠ‘ä½µç”¨èŠ³é¦™ç’°è½‰åŒ–é…¶æŠ‘åˆ¶åŠ‘ï¼Œé”æˆ ORR 23% èˆ‡ 79% çš„è‡¨åºŠç²ç›Šç‡ (CBR)ã€‚",
        "rationale": "åˆ©ç”¨å…§åˆ†æ³Œæ²»ç™‚é˜»æ–·æ¿€ç´ å—é«”ï¼Œä¸¦å”åŒ CDK4/6 æŠ‘åˆ¶åŠ‘é”æˆæ›´å¼·çš„ç´°èƒé€±æœŸåœæ»¯æ•ˆæ‡‰ã€‚",
        "regimen": "Ribociclib 400 mg QD (é€£æœ 3 é€±ä¼‘æ¯ 1 é€±) + Letrozole 2.5 mg QD (æŒçºŒæ¯æ—¥å£æœ)ã€‚",
        "inclusion": ["å¾©ç™¼æ€§ LGSOC", "ER/PR é™½æ€§è¡¨é”è€…å„ªå…ˆ", "ä¸é™å…ˆå‰æ²»ç™‚ç·šæ•¸"],
        "exclusion": ["ç„¡æ³•ååš¥å£æœè—¥ç‰©è€…", "ä½µç”¨å¼·æ•ˆ CYP3A4 èª˜å°åŠ‘"],
        "outcomes": "mPFS: 19.1m; ORR: 23%; CBR: 79%ã€‚"},

    {"cancer": "Ovarian", 
    "pos": "P-MT", 
    "sub_pos": ["HRD positive (wt)", "HRD negative (pHRD)"], 
    "name": "ğŸ“š DUO-O (ENGOT-OV46)", 
    "pharma": "AstraZeneca", 
    "drug": "Durvalumab + Olaparib + Bev",
    "pop_results": "ä¸€ç·šåˆä½µå…ç–«/æŠ—è¡€ç®¡/ï¼ˆéƒ¨åˆ†æ—ç¾¤åŠ PARPiï¼‰å¸¶ä¾†PFSæ”¹å–„ï¼›ç™¼è¡¨è³‡æ–™é¡¯ç¤ºã€ŒDurvalumabï¼‹Bevã€çµ„åˆå°æ¯”å°ç…§PFS HR 0.49ï¼ŒåŠ å…¥Olaparibå¾ŒPFS HR 0.61ï¼Œå‡¸é¡¯å¤šæ©Ÿè½‰ä¸€ç·šç­–ç•¥çš„æ–¹å‘ï¼ŒHRD+ ä¸‰è—¥çµ„ PFS HR 0.49; ITT HR 0.63",
    "rationale": "åˆ©ç”¨ IO + PARPi + anti-VEGF ä¸‰è—¥è¯ç”¨ï¼Œæ–¼ä¸€ç·šåæ‡‰å¾Œæ¸…é™¤å¾®å°æ®˜ç•™ç—…ç¶ä¸¦å»¶ç·©å¾©ç™¼ã€‚",
    "regimen": "backboneï¼šcarboplatin/paclitaxel + bevacizumab; éš¨æ©ŸåŠ å…¥ durvalumabï¼ˆèˆ‡åŒ–ç™‚ä½µç”¨ï¼‰ä¸¦åœ¨ç¶­æŒæœŸåˆä½µ durvalumab + bev Â± olaparib; Arm 3: Bevacizumab + Durvalumab + Olaparib (300mg bid) ç¶­æŒç›´è‡³ç–¾ç—…é€²å±•ã€‚",
    "inclusion": ["æ–°è¨ºæ–· FIGO III-IV æœŸä¸Šçš®æ€§åµå·¢ç™Œã€‚", "æ¥å— PDS æˆ– IDS ä¸”å°é‰‘é¡æœ‰åæ‡‰ã€‚", "ç‰¹åˆ¥é‡å° nonâ€“tumor BRCA-mutï¼ˆnon-tBRCAmï¼‰ã€ä¸¦ä»¥ HRD/ITT åšä¸»è¦åˆ†æã€‚"],
    "exclusion": ["ä¸é©åˆ bevã€‚", "æ—¢å¾€å…ç–«æ²»ç™‚ / PARPã€‚"],
    "outcomes": "åœ¨ HRD+ èˆ‡ ITTï¼ˆnon-tBRCAmï¼‰ æ—ç¾¤ï¼Œå« durvalumab+olaparib çš„ç­–ç•¥é”æˆ PFS ä¸»è¦çµ‚é»ï¼›OS ä»éœ€æ›´é•·è¿½è¹¤ï¼ŒHRD+ (non-BRCAm) PFS HR 0.49 (95% CI 0.34-0.69); ITT ITT HR 0.63ã€‚"},

    {"cancer": "Ovarian", "pos": "P-MT", "sub_pos": ["BRCA mutation"], 
        "name": "ğŸ“š SOLO-1", "pharma": "AZ", "drug": "Olaparib", 
        "pop_results": "BRCAm ä¸€ç·šç¶­æŒé‡‘æ¨™æº–ï¼š7 å¹´å­˜æ´»ç‡é” 67% (HR 0.33)ã€‚",
        "rationale": "é‡å°ä¸€ç·šå«é‰‘åŒ–ç™‚åæ‡‰è‰¯å¥½ä¹‹ BRCA çªè®Šæ‚£è€…ï¼Œåˆ©ç”¨ PARPi é”æˆã€åˆæˆè‡´æ­»ã€æ•ˆæœä»¥å»¶ç·©å¾©ç™¼ã€‚",
        "regimen": "Arm Aï¼šolaparib 300 mg BID maintenanceï¼ˆé€šå¸¸è‡³ 2 å¹´æˆ–é€²å±•ï¼‰ã€‚Arm Bï¼šplacebo maintenanceã€‚",
        "inclusion": ["newly diagnosed advanced ovarian cancerã€‚", "germline æˆ– somatic BRCA1/2 mutationã€‚", "ä¸€ç·š platinum åŒ–ç™‚å¾Œ CR/PRã€‚"],
        "exclusion": ["å…ˆå‰æ¥å—é PARP æŠ‘åˆ¶åŠ‘ã€‚", "æŒçºŒæ€§éª¨é«“æŠ‘åˆ¶æœªæ¢å¾©ã€‚"],
        "outcomes": "mPFS: 56.0m vs 13.8m (HR 0.30)ã€‚AEï¼šè²§è¡€ã€å™å¿ƒã€ç–²å€¦å¸¸è¦‹ï¼›éœ€ç›£æ¸¬è¡€çƒã€‚"},
    
    {"cancer": "Ovarian", "pos": "P-MT", "sub_pos": ["HRD positive / BRCA wt", "HRD negative (pHRD)"], 
        "name": "ğŸ“š PRIMA", "pharma": "GSK", "drug": "Niraparib", 
        "pop_results": "ä¸é™ BRCA ç‹€æ…‹çš„å…¨äººç¾¤ä¸€ç·šç¶­æŒï¼šHRD+ PFS HR 0.43ï¼›å…¨é«” ITT HR 0.62ï¼Œç¢ºç«‹ã€Œä¸éœ€é™ç¸®åˆ°BRCAã€çš„ä¸€ç·šç¶­æŒç­–ç•¥ã€‚",
        "rationale": "ä¸è«– HRD ç‹€æ…‹ï¼Œé€é PARPi å¼·åŒ–ä¸€ç·šåŒ–ç™‚å¾Œçš„ç¶­æŒç²ç›Šï¼Œç‰¹åˆ¥æ˜¯é‡å°é«˜é¢¨éšªæ—ç¾¤ã€‚",
        "regimen": "Arm Aï¼šniraparib maintenanceï¼ˆèµ·å§‹åŠ‘é‡å¯ä¾é«”é‡/è¡€å°æ¿èª¿æ•´ï¼›è‡³ 36 å€‹æœˆæˆ–é€²å±•ï¼‰ã€‚Arm Bï¼šplacebo maintenanceã€‚",
        "inclusion": ["newly diagnosed stage III/IVã€é«˜å¾©ç™¼é¢¨éšªã€‚", "ä¸€ç·š platinum åŒ–ç™‚å¾Œ CR/PRã€‚"],
        "exclusion": ["MDS/AML é¢¨éšªè©•ä¼°ç­‰ã€‚", "å…ˆå‰æ¥å—é PARP æŠ‘åˆ¶åŠ‘ã€‚", "æŒçºŒæ€§éª¨é«“æŠ‘åˆ¶æœªæ¢å¾©ã€‚"],
        "outcomes": "HRD+ PFS HR 0.43 (95% CI 0.31-0.59)ã€‚overall PFS HR 0.62ã€‚AEï¼šGrade â‰¥3 å¸¸è¦‹ è¡€å°æ¿ä¸‹é™ã€è²§è¡€ã€ä¸­æ€§çƒä½ä¸‹ã€‚"},
    
    {"cancer": "Ovarian", "pos": "P-MT", "sub_pos": ["HRD positive / BRCA wt"], 
        "name": "ğŸ“š PAOLA-1", "pharma": "AZ", "drug": "Olaparib + Bevacizumab", 
        "pop_results": "Olaparibï¼‹Bevacizumabç¶­æŒåœ¨å…¨é«”æ”¹å–„PFSï¼ˆHR 0.59ï¼‰ï¼Œåœ¨HRDé™½æ€§æ—ç¾¤æ•ˆç›Šæ›´å¤§ï¼ˆHR 0.33ï¼‰ï¼Œå¥ å®šã€ŒHRDå°å‘ã€åˆä½µç¶­æŒçš„æ¨™æº–ï¼ŒHRD+ é»ƒé‡‘çµ„åˆç¶­æŒï¼š5 å¹´ OS ç‡é” 75.2%ã€‚",
        "rationale": "çµåˆ anti-VEGFï¼ˆBevï¼‰é‡å¡‘è¡€ç®¡ç’°å¢ƒèˆ‡ PARPiï¼ˆOlaï¼‰æŠ‘åˆ¶ DNA ä¿®å¾©ä¹‹é›™é‡æ©Ÿè½‰ã€‚",
        "regimen": "æ‰€æœ‰æ‚£è€…å…ˆæ¥å—å« bevacizumab çš„ä¸€ç·šåŒ–ç™‚; Arm Aï¼šolaparib + bevacizumab maintenanceã€‚Arm Bï¼šbevacizumab maintenanceï¼ˆå°ç…§ï¼‰ã€‚",
        "inclusion": ["newly diagnosed stage III/IVã€é«˜å¾©ç™¼é¢¨éšªã€‚", "åŒ–ç™‚ + bev å¾Œ CR/PRã€‚", "ä¸¦åˆ†å±¤ HRD/BRCAã€‚"],
        "exclusion": ["ä¸é©åˆ bevï¼ˆå‡ºè¡€/å»”ç®¡/è¡€æ “é¢¨éšªï¼‰ã€‚", "å…ˆå‰æ¥å—é PARP æŠ‘åˆ¶åŠ‘ã€‚", "æŒçºŒæ€§éª¨é«“æŠ‘åˆ¶æœªæ¢å¾©ã€‚"],
        "outcomes": "PFS é¡¯è‘—æ”¹å–„ï¼ˆå°¤å…¶ HRD+ï¼‰ã€‚HRD+ 5yr OS: 75.2% vs 58.3% (HR 0.62)å…·è‡¨åºŠæ„ç¾©çš„ OS æ”¹å–„ã€‚AEï¼šPARPï¼ˆè²§è¡€ï¼‰+ bevï¼ˆé«˜è¡€å£“/è›‹ç™½å°¿ï¼‰æ¯’æ€§éœ€ä¸¦è¡Œç®¡ç†ã€‚"},
    
    {"cancer": "Ovarian", "pos": "P-MT", "sub_pos": ["BRCA mutation", "HRD positive / BRCA wt"], 
        "name": "ğŸ“š ATHENAâ€“MONO", "pharma": "Clovis", "drug": "Rucaparib", 
        "pop_results": "Rucaparibä¸€ç·šç¶­æŒæ”¹å–„PFSï¼ˆITTï¼šHR 0.52ï¼›HRDï¼šHR 0.47ï¼›HRD-negativeäº¦æœ‰è¨Šè™Ÿï¼šHR 0.65ï¼‰ï¼Œæ“´å……äº†ä¸€ç·šPARPiç¶­æŒçš„è­‰æ“šç‰ˆåœ–ã€‚",
        "rationale": "è­‰å¯¦ Rucaparib åœ¨ä¸€ç·šå«é‰‘åŒ–ç™‚åæ‡‰å¾Œçš„å–®è—¥ç¶­æŒåƒ¹å€¼ï¼Œä¸è«–å…¶ HRD ç‹€æ…‹ã€‚",
        "regimen": "Arm Aï¼šrucaparib maintenanceã€‚Arm Bï¼šplacebo maintenanceï¼ˆå°ç…§ï¼‰ã€‚",
        "inclusion": ["newly diagnosed advancedï¼ˆå¤šç‚º III/IVï¼‰ã€‚", "ä¸€ç·š platinum å¾Œ CR/PRã€‚", "æ¶µè“‹ HRD/HRPã€‚"],
        "exclusion": ["è‚åŠŸèƒ½ç•°å¸¸ã€‚", "å…ˆå‰æ¥å—é PARP æŠ‘åˆ¶åŠ‘ã€‚", "æŒçºŒæ€§éª¨é«“æŠ‘åˆ¶æœªæ¢å¾©ã€‚"],
        "outcomes": "ä¸»è¦çµ‚é»ç‚º PFSï¼Œåœ¨ HRD èˆ‡ ITT å‡å‘ˆç¾é¡¯è‘—ç²ç›Š: ITT PFS: 28.7m vs 11.3m (HR 0.52)ã€‚AEï¼šè²§è¡€ã€è‚é…µç´ ä¸Šå‡ç­‰ PARP å…¸å‹æ¯’æ€§ã€‚"},
    
    {"cancer": "Ovarian", "pos": "R-MT", "sub_pos": ["PARPi Maint"], 
        "name": "ğŸ“š NOVA", "pharma": "GSK", "drug": "Niraparib", 
        "pop_results": "å¾©ç™¼ã€é‰‘æ•æ„Ÿæƒ…å¢ƒä¸‹Niraparibç¶­æŒé¡¯è‘—å»¶é•·PFSï¼ˆgBRCAï¼šHR 0.27ï¼›non-gBRCAï¼šHR 0.45ï¼‰ï¼Œæ˜¯ã€Œå¾©ç™¼ç¶­æŒPARPiã€çš„ç¶“å…¸è©¦é©—",
        "rationale": "é¦–å€‹è­‰æ˜ PARPi åœ¨é‰‘é¡æ•æ„Ÿå¾©ç™¼ï¼ˆPSOCï¼‰æ‚£è€…ä¸­ï¼Œä¸è«– BRCA æ˜¯å¦çªè®Šçš†æœ‰ç²ç›Šçš„ç ”ç©¶ã€‚",
        "regimen": "Arm Aï¼šniraparib maintenanceã€‚Arm Bï¼šplacebo maintenanceï¼ˆå°ç…§ï¼‰ã€‚",
        "inclusion": ["platinum-sensitive recurrent ovarian cancerã€‚", "å°æœ€è¿‘ä¸€æ¬¡ platinum æœ‰åæ‡‰ã€‚", "åˆ† gBRCA èˆ‡ non-gBRCA cohortã€‚"],
        "exclusion": ["MDS/AML é¢¨éšªã€‚", "å…ˆå‰æ¥å—é PARP æŠ‘åˆ¶åŠ‘ã€‚", "æŒçºŒæ€§éª¨é«“æŠ‘åˆ¶æœªæ¢å¾©ã€‚"],
        "outcomes": "gBRCAm mPFS: 21.0m vs 5.5m (HR 0.27)ã€‚non-gBRCA HR 0.45ã€‚AEï¼šè¡€å°æ¿ä¸‹é™/è²§è¡€/ä¸­æ€§çƒä½ä¸‹å¸¸è¦‹ã€‚"},
    
    {"cancer": "Ovarian", "pos": "R-MT", "sub_pos": ["PARPi Maint"], 
        "name": "ğŸ“š ARIEL3", "pharma": "Clovis", "drug": "Rucaparib", 
        "pop_results": "Rucaparibç¶­æŒæ”¹å–„PFSï¼ˆæ„å‘æ²»ç™‚å…¨é«”ï¼šHR 0.36ï¼›BRCAçªè®Šï¼šHR 0.23ï¼‰ï¼Œæ”¯æŒä»¥åˆ†å±¤æ—ç¾¤æ–¹å¼ä½¿ç”¨PARPiï¼Œç²¾ç¢ºåˆ†æµç¶­æŒç²ç›Šï¼šBRCAm PFS HR 0.23ï¼›HRD+ HR 0.32ã€‚",
        "rationale": "åˆ©ç”¨ LOHï¼ˆé›œåˆæ€§ä¸Ÿå¤±ï¼‰æª¢æ¸¬è¼”åŠ©åˆ¤å®š HRD ç‹€æ…‹ï¼Œå°èˆª PARPi åœ¨å¾©ç™¼éšæ®µçš„ä½¿ç”¨ã€‚",
        "regimen": "Arm Aï¼šrucaparib maintenanceã€‚Arm Bï¼šplacebo maintenanceï¼ˆå°ç…§ï¼‰ã€‚",
        "inclusion": ["platinum-sensitive recurrent ovarian cancerã€‚", "å° platinum æœ‰åæ‡‰ã€‚", "åˆ†å±¤ BRCA-mut / HRD / ITTã€‚"],
        "exclusion": ["é‡å¤§å…±ç—…ã€‚", "å…ˆå‰æ¥å—é PARP æŠ‘åˆ¶åŠ‘ã€‚", "æŒçºŒæ€§éª¨é«“æŠ‘åˆ¶æœªæ¢å¾©ã€‚"],
        "outcomes": "BRCAm mPFS 16.6m vs 5.4m (HR 0.23)ï¼›HRD HR ~0.32ï¼›ITT HR ~0.36ã€‚AEï¼šè²§è¡€ã€è‚é…µç´ ä¸Šå‡ç­‰ã€‚"},
    
    {"cancer": "Ovarian", "pos": "R-MT", "sub_pos": ["PARPi Maint"], 
        "name": "ğŸ“š SOLO2", "pharma": "AZ", "drug": "Olaparib", 
        "pop_results": "Olaparibç¶­æŒå¯å»¶é•·PFSï¼ˆHR 0.30ï¼‰ï¼Œä½†æœ€çµ‚OSå„ªå‹¢ä¸æ˜é¡¯ï¼ˆOS HR 0.74ã€æœªé”é¡¯è‘—ï¼‰ï¼Œæ˜¯è§£è®€ã€Œäº¤å‰æ²»ç™‚/å¾Œç·šPARPiä½¿ç”¨ã€å½±éŸ¿OSçš„ä»£è¡¨æ¡ˆä¾‹ï¼Œå¾©ç™¼ç¶­æŒç”Ÿå­˜çªç ´ï¼šBRCAm æ—ç¾¤ mOS é¡¯è‘—å»¶é•·è‡³ 51.7m (HR 0.74)ã€‚",
        "rationale": "ç¢ºèª Olaparib åœ¨å¾©ç™¼ç¶­æŒéšæ®µèƒ½å°‡ PFS ç²ç›Šè½‰åŒ–ç‚ºæœ€çµ‚ OS ç²ç›Šã€‚",
        "regimen": "Arm Aï¼šolaparib tablets maintenanceã€‚Arm Bï¼šplacebo maintenanceï¼ˆå°ç…§ï¼‰ã€‚",
        "inclusion": ["platinum-sensitive recurrent ovarian cancerã€‚", "å° platinum æœ‰åæ‡‰ã€‚", "BRCA1/2 mutationã€‚"],
        "exclusion": ["é‡å¤§å…±ç—…ã€‚", "å…ˆå‰æ¥å—é PARP æŠ‘åˆ¶åŠ‘ã€‚", "æŒçºŒæ€§éª¨é«“æŠ‘åˆ¶æœªæ¢å¾©ã€‚"],
        "outcomes": "mOS: 51.7m vs 38.8m (HR 0.74)ã€‚PFS é¡¯è‘—æ”¹å–„ï¼ŒHR ç´„ 0.30ï¼Œæœ€çµ‚ OS åˆ†æé¡¯ç¤º median OS +12.9 monthsã€‚AEï¼šè²§è¡€ã€å™å¿ƒã€ç–²å€¦ã€‚ "},

    # ==========================
    # === Ongoing Trials (8æ ¸å¿ƒæ¥µé‡åŒ–) ===
    # ==========================
    {"cancer": "Endometrial", "name": "ğŸ“ MK2870-033", "pharma": "MSD", "drug": "Sac-TMT + Pembrolizumab", "pos": "P-MT", "sub_pos": ["Maintenance Therapy"], "type": "Ongoing",
     "pop_results": "ç”¨ TROP2-ADCå¢åŠ è…«ç˜¤ç´°èƒæ®ºå‚·ä¸¦èˆ‡ PD-1 æŠ‘åˆ¶ä½µç”¨ï¼Œç›®æ¨™æ˜¯è£œè¶³ã€ŒpMMR å­å®®å…§è†œç™Œå°å…ç–«å–®è—¥åæ‡‰è¼ƒå·®ã€éœ€è¦æ›´å¼·çš„ä¸€ç·š/ç¶­æŒç­–ç•¥ã€çš„ç¼ºå£ã€‚",
     "rationale": "æ¨™é¶ Trop-2 ADC (Sac-TMT) å”åŒ PD-1ã€‚é€é ADC èª˜å°ä¹‹ ICD æ”¹å–„å¾®ç’°å¢ƒï¼Œæ—¨åœ¨æå‡ pMMR æˆ– NSMP æ‚£è€…ä¸€ç·šç¶­æŒéšæ®µæ‡‰ç­”æ·±åº¦èˆ‡æŒçºŒæ™‚é–“ã€‚",
     "regimen": "Arm A (åˆ†çµ„ 1): Sac-TMT 5mg/kg Q6W + Pembrolizumab 400mg Q6W ç¶­æŒæ²»ç™‚ç›´åˆ° PDã€‚ Arm B (åˆ†çµ„ 2): é†«å¸«é¸æ“‡ç¶­æŒæ–¹æ¡ˆ (å°ç…§çµ„)ã€‚",
     "inclusion": ["æ–°è¨ºæ–· pMMR/MSS å­å®®å…§è†œç™Œ (ä¸­å¿ƒ IHC æª¢æ¸¬ç¢ºèª)ã€‚", "FIGO III-IV æœŸã€ä¸€ç·šå«é‰‘åŒ–ç™‚ + Pembrolizumab å¾Œé” CR/PRã€‚"],
     "exclusion": ["å…ˆå‰æ¥å—éé‡å°å¾©ç™¼ç—…ç¶ä¹‹ç³»çµ± IO æ²»ç™‚ã€‚", "çµ„ç¹”å­¸ç‚ºå­å®®è‚‰ç˜¤ (Sarcoma)ã€‚"]},

    {"cancer": "Ovarian", "name": "ğŸ“ FRAmework-01 (LY4170156)", "pharma": "Eli Lilly", "drug": "LY4170156 + Bevacizumab", "pos": "R-TX", "sub_pos": ["PROC (Resistant Recur)", "PSOC (Sensitive Recur)"], "type": "Ongoing",
     "pop_results": "ä»¥ FRÎ± æ¨™çš„ ADCï¼ˆæŠŠç´°èƒæ¯’è¼‰è·ç²¾æº–é€å…¥è…«ç˜¤ï¼‰æ”»å…‹é‰‘æŠ—è—¥åµå·¢ç™Œï¼Œä¸¦å˜—è©¦æ“´å¤§åˆ°æ›´å¤š FRÎ± è¡¨ç¾ç¯„åœ/æˆ–æ­é… bevï¼Œç›®çš„åœ¨å½Œè£œã€Œé‰‘æŠ—è—¥æœŸæœ‰æ•ˆä¸”å¯è€å—çš„ç³»çµ±æ²»ç™‚ä»ä¸è¶³ã€FRÎ±-ADC å—æƒ æ—ç¾¤ä»æœ‰é™ã€çš„ç¼ºå£ã€‚",
     "rationale": "æ¨™é¶ FRÎ± ADC è¯ç”¨ anti-VEGFã€‚åˆ©ç”¨ Bevacizumab è¡€ç®¡èª¿ç¯€ä½œç”¨é™ä½è…«ç˜¤é–“è³ªå£“ï¼Œæå‡ ADC æ–¼å¯¦é«”è…«ç˜¤å…§çš„æ»²é€æ·±åº¦æŒ‘æˆ°è€è—¥ç“¶é ¸ã€‚",
     "regimen": "PROC éšŠåˆ—åˆ†çµ„ï¼š Arm A: LY 3.0mg/kg + Bev 15mg/kg Q3W; Arm B: LY 4.0mg/kg + Bev 15mg/kg Q3Wã€‚ PSOC éšŠåˆ— (PFI 6-12m): Arm C: LY 3.0mg/kg + Bev 15mg/kg Q3Wã€‚ å°ç…§çµ„ (Arm D): é†«å¸«é¸æ“‡åŒ–ç™‚ SoCã€‚",
     "inclusion": ["ç¶“æª¢æ¸¬ç¢ºèª FRÎ± è¡¨é”é™½æ€§ (IHC)ã€‚", "æœ€å¾Œé‰‘é¡å¾Œé€²å±•ä¹‹ PROC æˆ– PSOC (PFI 90d-365d)ã€‚"],
     "exclusion": ["æ›¾ç”¨éé‡å° FRÎ± ä¹‹ ADC (å¦‚ Enhertu æ›¾è©¦éè€…éœ€è©•ä¼°)ã€‚", "æ´»å‹•æ€§é–“è³ªæ€§è‚ºç—… (ILD)ã€‚"]},

    {"cancer": "Endometrial", "name": "ğŸ“ GU-US-682-6769", "pharma": "Gilead", "drug": "SG (Trodelvy)", "pos": "R-TX", "sub_pos": ["Recurrent EC"], "type": "Ongoing",
     "pop_results": "é‡å°ã€Œé‰‘é¡åŒ–ç™‚+PD-(L)1 å¾Œä»é€²å±•ã€é å¾Œå·®ä¸”å¾Œç·šç¼ºä¹æœ‰æ•ˆæ–¹æ¡ˆã€çš„æ—ç¾¤ï¼Œè©•ä¼° **TROP2-ADCï¼ˆsacituzumab govitecanï¼Œè¼‰è· SN-38ï¼‰**èƒ½å¦åœ¨ PFS/OS è¶…è¶Šå‚³çµ±å–®è—¥åŒ–ç™‚ï¼Œå¡«è£œå¾Œç·šæ²»ç™‚ç©ºçª—ã€‚",
     "rationale": "é‡å° Trop-2 æ¨™é¶ã€‚åˆ©ç”¨ SN-38 è¼‰è·å¼•ç™¼å¼·åŠ› DNA æå‚·ï¼Œå°ˆæ”»é‰‘é¡èˆ‡å…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘ (ICI) å¤±æ•—å¾Œä¹‹å¾©ç™¼æ•‘æ´ã€‚",
     "regimen": "Sacituzumab govitecan 10mg/kg (Day 1, Day 8) æ¯ 21 å¤©ç‚ºä¸€é€±æœŸ (Q21D) ç›´è‡³ç–¾ç—…é€²å±•ã€‚",
     "inclusion": ["å¾©ç™¼æ€§ EC (ä¸å«è‚‰ç˜¤)ã€‚", "å…ˆå‰æ›¾æ¥å—éè‡³å°‘ä¸€æ¬¡å«é‰‘åŒ–ç™‚åŠ PD-1/L1 å¤±æ•—é€²å±•è€…ã€‚", "ECOG 0-1ã€‚"]},

    {"cancer": "Ovarian", "name": "ğŸ“ DOVE", "pharma": "GSK", "drug": "Dostarlimab + Bevacizumab", "pos": "R-TX", "sub_pos": ["PROC (Resistant Recur)"], "type": "Ongoing",
     "pop_results": "ç”¨ **PD-1 æŠ‘åˆ¶ï¼ˆdostarlimabï¼‰**å–®ç”¨æˆ–åˆä½µ æŠ—è¡€ç®¡æ–°ç”Ÿï¼ˆbevacizumabï¼‰ï¼Œæƒ³æŠŠã€Œå°åŒ–ç™‚ç‰¹åˆ¥ä¸æ•æ„Ÿã€å¾©ç™¼å¾Œé¸æ“‡å¾ˆå°‘ã€çš„é€æ˜ç´°èƒç™Œï¼Œå¾å‚³çµ±åŒ–ç™‚å°å‘è½‰æˆå…ç–«/å…ç–«åˆä½µæŠ—è¡€ç®¡æ–°ç”Ÿçš„æ–°ç­–ç•¥ã€‚",
     "rationale": "é‡å° OCCC é€æ˜ç´°èƒç™Œã€‚åˆ©ç”¨ PD-1 + anti-VEGF é›™é‡é˜»æ–·æ”¹å–„å…¶ç‰¹æœ‰ä¸”é«˜åº¦å…ç–«æŠ‘åˆ¶ä¹‹å¾®ç’°å¢ƒã€‚",
     "regimen": "Dostarlimab 1000mg Q6W + Bevacizumab 15mg/kg Q3W ç›´è‡³é€²å±•ã€‚"},

    {"cancer": "Ovarian", "name": "ğŸ“ DS8201-772 (Enhertu)", "pharma": "AstraZeneca", "drug": "T-DXd", "pos": "P-MT", "sub_pos": ["BRCA mutation", "HRD positive (wt)"], "type": "Ongoing",
     "pop_results": "ç”¨ **HER2-ADCï¼ˆT-DXdï¼‰**åœ¨ä¸€ç·šæ²»ç™‚å¾Œåšç¶­æŒï¼Œä¸¦åˆä½µ bevacizumabï¼Œç„æº–ã€ŒHER2 è¡¨ç¾çš„åµå·¢ç™Œäºç¾¤ç¼ºä¹æ˜ç¢ºçš„æ¨™é¶ç¶­æŒæ¨™æº–ã€ä»æ˜“å¾©ç™¼ã€é€™å€‹ unmet needï¼Œå¸Œæœ›å»¶é•·ç¶­æŒæœŸæ§åˆ¶èˆ‡å­˜æ´»ã€‚",
     "rationale": "æ¨™é¶ HER2 ADC ç”¨æ–¼ç¶­æŒã€‚åˆ©ç”¨ T-DXd æ¥µé«˜ DAR (8) å„ªå‹¢æ¸…é™¤åŒ–ç™‚å¾Œæ®˜é¤˜ä¹‹ HER2 è¡¨ç¾å¾®å°ç—…ç¶ã€‚",
     "regimen": "Trastuzumab deruxtecan 5.4mg/kg IV Q3W ç¶­æŒè‡³é€²å±•ã€‚"},
]

# --- 3. AI æ¨¡å‹å·¡é‚èˆ‡è¯å‹•åŠŸèƒ½ ---
def get_gemini_model():
    try:
        available_models = [m.name for m in genai.list_models() if 'generateContent' in m.supported_generation_methods]
        target_model = next((m for m in available_models if 'gemini-1.5-flash' in m), None)
        if not target_model: target_model = next((m for m in available_models if 'gemini-pro' in m), None)
        if target_model: return genai.GenerativeModel(target_model)
    except: return None

# --- 4. å´é‚Šæ¬„ï¼šæ±ºç­–åŠ©ç† ---
with st.sidebar:
    st.markdown("<h3 style='color: #6A1B9A;'>ğŸ¤– AI å¯¦è­‰åª’åˆåŠ©ç†</h3>", unsafe_allow_html=True)
    api_key = st.text_input("Gemini API Key", type="password")
    with st.expander("âœ¨ æ‚£è€…ç—…æ­·æ•¸æ“šæ·±åº¦åˆ†æ", expanded=True):
        p_notes = st.text_area("è¼¸å…¥æ‘˜è¦ (å«åˆ†æœŸ/ç´°èƒ/æ¨™è¨˜)", placeholder="ä¾‹å¦‚ï¼šEC Stage III, dMMR, p53 mutation, HER2 2+...", height=250)
        if st.button("ğŸš€ é–‹å§‹åª’åˆåˆ†æ"):
            if api_key and p_notes:
                try:
                    genai.configure(api_key=api_key)
                    model = get_gemini_model()
                    prompt = f"åˆ†æç—…æ­·ï¼š{p_notes}ã€‚è«‹åƒè€ƒå¯¦è­‰åº«ï¼š{all_trials_db}ã€‚å»ºè­°é©åˆè·¯å¾‘èˆ‡è©¦é©—ç†ç”±ã€‚"
                    st.write(model.generate_content(prompt).text)
                except Exception as e: st.error(f"AI ç•°å¸¸: {e}")

# --- 5. ä¸»é é¢ï¼šå°èˆªåœ°åœ–ä½ˆå±€ ---
st.markdown("<div class='main-title'>å©¦ç™Œè‡¨åºŠå°èˆªå„€è¡¨æ¿ (2026 æ——è‰¦æœ€çµ‚æ¥µé‡æ•´åˆç‰ˆ)</div>", unsafe_allow_html=True)
cancer_type = st.radio("ç¬¬ä¸€æ­¥ï¼šé¸æ“‡ç™Œç—‡é¡å‹", ["Endometrial", "Ovarian", "Cervical"], horizontal=True)

cols = st.columns(len(guidelines_nested[cancer_type]))
stages_data = guidelines_nested[cancer_type]

for i, stage in enumerate(stages_data):
    with cols[i]:
        st.markdown(f"""<div class='big-stage-card card-{stage['css']}'><div class='big-stage-header header-{stage['css']}'>{stage['header']}</div>""", unsafe_allow_html=True)
        for sub in stage['subs']:
            st.markdown(f"""<div class='sub-block'><div class='sub-block-title'>ğŸ“˜ {sub['title']}</div><div class='sub-block-content'>{sub['content']}</div>""", unsafe_allow_html=True)
            
            # åˆä½µå¯¦è­‰æ¸²æŸ“æŒ‰éˆ•
            rel_trials = [t for t in (all_trials_db) if t["cancer"] == cancer_type and t["pos"] == stage["id"] and any(s in sub["title"] for s in t["sub_pos"])]
            for t in rel_trials:
                label = f"{t.get('pharma', 'N/A')} | {t['name']} | {t['drug']}"
                with st.popover(label, use_container_width=True):
                    # å±•ç¤ºç°¡å–®ç™‚æ•ˆå°çµè«– (åœ–ä¸‰ä¿®å¾©)
                    st.success(f"**æ ¸å¿ƒçµè«–æ‘˜è¦:** {t.get('pop_results', 'æ‹›å‹Ÿä¸­/è©³è¦‹æ·±åº¦çœ‹æ¿')}")
                    # åŒæ­¥è¯å‹•é‚è¼¯ï¼šé»æ“Šè§¸ç™¼ rerun åŒæ­¥çœ‹æ¿
                    unique_key = f"sync_{t['name']}_{cancer_type}_{stage['id']}_{sub['title'].replace(' ', '')}"
                    if st.button("ğŸ“Š åŒæ­¥çœ‹æ¿ç´°ç¯€", key=unique_key):
                        st.session_state.selected_trial = t['name']
                        st.rerun() 
            st.markdown("</div>", unsafe_allow_html=True)
        st.markdown("</div>", unsafe_allow_html=True)

# --- 6. æ·±åº¦æ•¸æ“šçœ‹æ¿ (æ¥µé‡åŒ–è³‡è¨Šå±•ç¤ºå€) ---
st.divider()
st.subheader("ğŸ“‹ è‡¨åºŠç ”ç©¶æ¥µé‡åŒ–æ•¸æ“šåº« (Published Milestones & Ongoing Trials)")
filtered_names = [t["name"] for t in all_trials_db if t["cancer"] == cancer_type]

if not filtered_names:
    st.info("è©²ç™Œç—‡é¡åˆ¥ä¸‹ç›®å‰ç„¡é©ç”¨å¯¦è­‰æˆ–è¨ˆç•«ã€‚")
else:
    try: curr_idx = filtered_names.index(st.session_state.selected_trial)
    except: curr_idx = 0

    selected_name = st.selectbox("ğŸ¯ å¿«é€Ÿé¸æ“‡ç ”ç©¶è¨ˆç•«ä»¥æŸ¥é–±åˆ†çµ„èˆ‡æ•¸æ“šï¼š", filtered_names, index=curr_idx, key="trial_selector")
    st.session_state.selected_trial = selected_name
    t_obj = next(it for it in all_trials_db if it["name"] == selected_name)

    st.markdown(f"<div class='detail-section'>", unsafe_allow_html=True)
    st.markdown(f"<h2 style='color:#004D40; border-bottom:3px solid #E0E0E0; padding-bottom:10px; font-weight:900;'>ğŸ“‹ {t_obj['name']} æ·±åº¦åˆ†æå ±å‘Š</h2>", unsafe_allow_html=True)

    r1, r2 = st.columns([1.3, 1])
    with r1:
        st.markdown("<div style='background:#E3F2FD; border-left:10px solid #1976D2; padding:15px; border-radius:10px;'><b>ğŸ’‰ Rationale & Regimen (æ©Ÿè½‰èˆ‡åˆ†çµ„çµ¦è—¥)</b></div>", unsafe_allow_html=True)
        st.write(f"**è—¥å» :** {t_obj.get('pharma', 'N/A')} | **æ ¸å¿ƒé…æ–¹:** {t_obj['drug']}")
        
        # æ¥µé‡åŒ–çµ¦è—¥æ–¹æ¡ˆ (Dosing Protocol) - è£œé½Šåˆ†çµ„ç´°ç¯€
        st.markdown("<div class='regimen-box'><b>åˆ†çµ„çµ¦è—¥æ–¹å¼ (Regimen per Arm):</b><br>" + t_obj.get('regimen', 'æ­£åœ¨è£œé½Šåˆ†çµ„çµ¦è—¥ç´°ç¯€ã€‚') + "</div>", unsafe_allow_html=True)
        
        st.success(f"**ç§‘å­¸ç†æ“š (Scientific Rationale):** {t_obj.get('rationale', 'æ—¨åœ¨æŒ‘æˆ° SoC ç“¶é ¸æå‡ç²ç›Šã€‚')}")

    with r2:
        st.markdown("<div style='background:#FFF8E1; border-left:8px solid #FBC02D; padding:15px; border-radius:10px;'><b>ğŸ“ˆ Key Outcomes (æœ€æ–°ç”Ÿå­˜èˆ‡ç·©è§£æŒ‡æ¨™)</b></div>", unsafe_allow_html=True)
        st.markdown(f"""
            <div style='text-align:center; background:white; padding:15px; border:2px solid #FFE082; border-radius:12px;'>
                <div style='font-size: 14px; color: #795548; font-weight:700; margin-bottom:5px;'>Survival Metrics (PFS/OS/HR/ORR)</div>
                <div class='hr-big-val'>{t_obj.get('outcomes', t_obj.get('results_short', 'Ongoing Recruitment'))}</div>
            </div>
        """, unsafe_allow_html=True)
        

    st.divider()
    r3, r4 = st.columns(2)
    with r3:
        st.markdown("<div style='background:#E8F5E9; border-left:8px solid #2E7D32; padding:15px; border-radius:10px;'><b>âœ… Inclusion Criteria (é—œéµç´å…¥æ¨™æº–)</b></div>", unsafe_allow_html=True)
        for inc in t_obj.get('inclusion', ['ç¬¦åˆåˆ†å­æ¨™è¨˜åˆ†å‹èˆ‡å‰ç·šè¦å®šã€‚']): st.write(f"â€¢ **{inc}**")
    with r4:
        st.markdown("<div style='background:#FFEBEE; border-left:8px solid #C62828; padding:15px; border-radius:10px;'><b>âŒ Exclusion Criteria (é—œéµæ’é™¤æ¨™æº–)</b></div>", unsafe_allow_html=True)
        for exc in t_obj.get('exclusion', ['æ’é™¤è‡Ÿå™¨åŠŸèƒ½ç•°å¸¸æˆ–æ´»å‹•æ€§è‡ªé«”å…ç–«ç–¾ç—…ã€‚']): st.write(f"â€¢ **{exc}**")
    st.markdown("</div>", unsafe_allow_html=True)
